Page last updated: 2024-12-04

clomipramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Clomipramine is a tricyclic antidepressant (TCA) that is primarily used to treat obsessive-compulsive disorder (OCD). It is also used to treat other conditions, such as depression, panic disorder, and premenstrual dysphoric disorder. Clomipramine is a potent inhibitor of serotonin reuptake and has a significant affinity for the 5-HT2A receptor. Clomipramine was synthesized in 1957 by a team of scientists at Ciba-Geigy (now Novartis). It was first marketed in 1961 under the brand name Anafranil. Clomipramine's effects on the brain are thought to be mediated by its ability to increase serotonin levels in the synapses. Serotonin is a neurotransmitter that plays a role in mood, sleep, appetite, and other functions. Clomipramine is an effective treatment for OCD, but it can cause side effects such as drowsiness, dry mouth, blurred vision, and constipation. It is also important to note that clomipramine can interact with other medications, so it is important to talk to your doctor about all the medications you are taking before starting clomipramine. Clomipramine has been studied extensively, and there is a large body of research on its effectiveness and safety. It is a valuable treatment option for people with OCD and other conditions. Clomipramine is a potent inhibitor of serotonin reuptake and has a significant affinity for the 5-HT2A receptor. It is also a relatively selective inhibitor of the 5-HT1A receptor. Clomipramine is considered a first-line treatment for OCD, and it is often effective in treating patients who have not responded to other treatments. Clomipramine is also effective in treating patients with anxiety disorders, such as panic disorder and social phobia. Clomipramine is a relatively safe and effective treatment for OCD and other conditions, but it is important to note that it can cause side effects and interact with other medications. It is important to talk to your doctor about all the medications you are taking before starting clomipramine.'

Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

sodium green: a new fluorescent sodium indicator; no further information available 3/96 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sodium green : A quaternary ammonium salt that is the tetrakis(N,N,N-trimethylmethammonium) salt of 5-({[4-(13-{4-[({3-carboxy-4-[(2,7-dichloro-6-hydroxy-3-oxo-3H-xanthen-9-yl)methyl]phenyl}carbonyl)amino]-2,5-bis(methyloxy)phenyl}-1,4,10-trioxa-7,13-diazacyclopentadecan-7-yl)-2-hydroxy-5-(methyloxy)phenyl]amino}carbonyl)-2-(2,7-dichloro-6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2801
CHEMBL ID415
CHEBI ID47780
SCHEMBL ID35423
MeSH IDM0004598
PubMed CID56927700
CHEBI ID52270
MeSH IDM0004598

Synonyms (171)

Synonym
BIDD:PXR0151
BRD-K52989797-001-01-1
BRD-K52989797-003-05-8
3-(9-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethylpropan-1-amine
gtpl2398
5h-dibenz[b, 10,11-dihydro-3-chloro-5-[3-(dimethylamino)propyl]-
5h-dibenz[b, 3-chloro-10,11-dihydro-n,n-dimethyl-
wln: t c676 bn & t & j b3n1 & 1 eg
3-chloro-5-[3-(dimethylamino)propyl]-10,f]azepine
g 34586
anafranil base
nsc169865
monochlorimipramine
5h-dibenz[b, 3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-
nsc-169865
anafranil (free base)
hydiphen
3-chloroimipramine
chlorimipramine
KBIO1_000797
DIVK1C_000797
3-chloro-10,11-dihydro-n,n-dimethyl-5h-dibenz(b,f)azepine-5-propanamine
3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5h-dibenz(b,f)azepine
10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-5h-dibenz(b,f)azepine
5h-dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-
nsc 169865
5h-dibenz(b,f)azepine, 10,11-dihydro-3-chloro-5-(3-(dimethylamino)propyl)-
5h-dibenz(b,f)azepine, 3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro- (8ci)
5h-dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-n,n-dimethyl-
clomipraminum [inn-latin]
brn 1323477
einecs 206-144-2
chlomipramine
clomipramine [inn:ban]
clomipramina [inn-spanish]
SPECTRUM_000444
BIOMOL-NT_000151
lopac-c-7291
NCGC00024355-02
tocris-0457
NCGC00015264-02
NCGC00015264-01
cas-17321-77-6
BPBIO1_000661
D07727
clomipramine (inn)
PRESTWICK3_000269
BSPBIO_003294
BPBIO1_000130
OPREA1_312582
SPECTRUM5_001235
IDI1_000797
PRESTWICK2_000269
PDSP2_000240
LOPAC0_000307
AB00053695
303-49-1
clomipramine
C06918
5h-dibenz[b,f]azepine-5-propanamine, 3-chloro-10,11-dihydro-n,n-dimethyl-
3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethyl-propan-1-amine
DB01242
anafranil (tn)
NCGC00024355-05
CHEBI:47780 ,
3-(3-chloro-10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethyl-1-propanamine
3-(3-chloro-10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethylpropan-1-amine
KBIOSS_000924
KBIO2_006060
KBIOGR_000759
KBIO3_002514
KBIO2_003492
KBIO2_000924
SPBIO_002337
NINDS_000797
SPECTRUM2_001729
PRESTWICK1_000269
PRESTWICK0_000269
SPBIO_001778
SPECTRUM4_000350
SPECTRUM3_001707
PDSP1_000241
BSPBIO_000118
NCGC00015264-03
NCGC00024355-04
NCGC00015264-09
AKOS001487687
L000890
CHEMBL415
3-chloro-iminodibenzyl
clomicalm
anapramine
3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethylpropan-1-amine
NCGC00015264-08
unii-nuv44l116d
hsdb 7746
clomipramina
clomipraminum
nuv44l116d ,
5-20-08-00103 (beilstein handbook reference)
STK534842
cas-303-49-1
dtxcid602844
dtxsid6022844 ,
tox21_110117
CCG-110307
NCGC00015264-10
NCGC00015264-05
NCGC00015264-04
NCGC00015264-06
NCGC00015264-07
AB05476
clomipramine [ema epar veterinary]
clomipramine [mi]
clomipramine [who-dd]
clomipramine [inn]
clomipramine [hsdb]
clomipramine [vandf]
SCHEMBL35423
tox21_110117_1
NCGC00015264-13
AB00053695-14
GDLIGKIOYRNHDA-UHFFFAOYSA-N
3-(3-chloro-10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)-n,n-dimethyl-1-propanamine #
5h-dibenz[b,f]azepine, 3-chloro-5-[3-(dimethylamino)propyl]-10,11-dihydro-
bdbm77970
3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethylpropan-1-amine;hydrochloride
clomiprimine
3-(2-chloranyl-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethyl-propan-1-amine;hydrochloride
3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)propyl-dimethyl-amine;hydrochloride
3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethyl-1-propanamine;hydrochloride
cid_68539
HMS3428J14
AB00053695_16
AB00053695_15
(3-{5-chloro-2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine
n-[3-(3-chloro-10,11-dihydro-5h-dibenzo[b,f]azepin-5-yl)propyl]-n,n-dimethylamine
3-chloro-10,11-dihydro-n,n-dimethyl-5h-dibenz[b,f]azepine-5-propanamine
SBI-0050295.P003
3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5h-dibenz[b,f]azepine
DS-6718
2241983-11-7
n,n-dimethyl-7-chloro-10,11-dihydro-5h-dibenzo[b,f]azepine-5-propanamine-2,4-d2
mfcd31699980
SY246341
mfcd00242755
Q58713
2-bromo-3-ethoxy-6-fluorophenylboronicacid
BRD-K52989797-003-16-5
SDCCGSBI-0050295.P004
NCGC00015264-25
AMY32531
anapramine; chlorimipramine;g 34586; nsc 169865
C74557
CS-0012495
HY-B0457A
cim
maronil
n06aa04
clomipraminum (inn-latin)
clomipramina (inn-spanish)
3-(3-chloro-10,11-dihydro-5h-dibenzo(b,f)azepin-5-yl)-n,n-dimethyl-1-propanamine
3-(3-chloro-10,11-dihydro-5h-dibenzo(b,f)azepin-5-yl)-n,n-dimethylpropan-1-amine
clomipramine (ema epar veterinary)
3-chloro-5-(3-dimethylamino)-propyl)-10,11-dihydro-5h-dibenz(b,f)azepine
EN300-6733614
(3-{5-chloro-2-azatricyclo[9.4.0.0,3,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}propyl)dimethylamine
tetrakis(n,n,n-trimethylmethanaminium) 5-({[4-(13-{4-[({3-carboxylato-4-[(2,7-dichloro-6-oxido-3-oxo-3h-xanthen-9-yl)methyl]phenyl}carbonyl)amino]-2,5-bis(methyloxy)phenyl}-1,4,10-trioxa-7,13-diazacyclopentadecan-7-yl)-2-hydroxy-5-(methyloxy)phenyl]amino}
CHEBI:52270
sodium green
Q27123341

Research Excerpts

Overview

Clomipramine (CIMI) is an effective treatment for obsessive-compulsive disorder in patients who have failed to respond to trials of selective serotonin transport inhibitors (eg, sertraline) It is a tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine by indirect actions on the dopaminergic system.

ExcerptReferenceRelevance
"Clomipramine (CIMI) is an effective treatment for obsessive-compulsive disorder in patients who have failed to respond to trials of selective serotonin transport inhibitors (eg, sertraline). "( Personalized Medicine in the Treatment of a Patient With Obsessive-Compulsive Disorder With Clomipramine.
Preskorn, SH; Rode, R, 2023
)
2.57
"Clomipramine is an FDA-approved antidepressant drug, able to inhibit in vitro the E3 ubiquitin ligase Itch and potentiate the pro-apoptotic effects of DNA damaging induced agents in several cancer cell lines."( Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells.
Bongiorno-Borbone, L; Compagnone, M; De Maria, R; Eramo, A; Giacobbe, A; Melino, G; Peschiaroli, A, 2015
)
1.42
"Clomipramine is a tricyclic antidepressant drug that inhibits Trypanosoma cruzi's trypanothione reductase, provoking the death of the parasite and preventing the cardiac damage when used for the treatment of acutely infected mice."( Chemotherapy of chronic indeterminate Chagas disease: a novel approach to treatment.
Bazán, PC; Enders, J; Fernández, AR; Fretes, R; Lo Presti, MS; Paglini-Oliva, P; Rivarola, HW; Triquell, MF, 2008
)
1.07
"Clomipramine is a tricyclic antidepressant for psychiatric disorders that can induce QT prolongation, which may lead to torsades de pointes. "( Clomipramine block of the hERG K+ channel: accessibility to F656 and Y652.
Choe, H; Chong, SH; Hong, HK; Jo, SH; Jung, SJ; Won, KH, 2008
)
3.23
"Clomipramine is a tricyclic antidepressant that inhibits the reuptake of serotonin and norepinephrine by indirect actions on the dopaminergic system and LHPA axis."( Effect of repeated restraint stress and clomipramine on Na+/K+-ATPase activity and behavior in rats.
Amaral, GP; Balk, Rde S; Barbosa, NB; Barcelos, R; Bridi, JC; Carvalho, NR; Dias, GR; Dobrachinski, F; Portella, Rde L; Rocha, JB; Silva, MH; Soares, FA, 2011
)
1.36
"Clomipramine is an antidepressive drug with a pro-depressive paradoxical effect in adult rats when administrated neonatally."( Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression).
Adris, S; Argibay, P; Burgos, V; Cassano, P; Hidalgo, A,
)
1.08
"Clomipramine is a lipid-soluble tricyclic antidepressant with significant cardiovascular depressant activity in human overdose."( Intralipid outperforms sodium bicarbonate in a rabbit model of clomipramine toxicity.
Cave, G; Harvey, M, 2007
)
1.3
"Clomipramine is a CYP2D6 inhibitor and may change the CYP2D6 phenotype status (EM into PM)."( [The influence of clomipramine on CYP2D6 activity].
Beszłej, JA; Chlebowska, I; Grzesiak, M; Kiejna, A; Milejski, P; Orzechowska-Juzwenko, K; Szewczuk-Bogusławska, M,
)
1.91
"Clomipramine is a tricyclic antidepressant widely used."( [Clomipramine and desmethylclomipramine: relationship between plasma levels and clinical effect (author's transl)].
Allers, G; Jounet, JM; Vandel, B; Vandel, S; Volmat, R, 1981
)
1.89
"Clomipramine is a tricyclic antidepressant that was the first effective agent in the treatment of OCD. "( Clomipramine and obsessive-compulsive disorder.
Lynch, KA; Scahill, L,
)
3.02
"Clomipramine is an effective antiobsessional agent, but its possible antiobsessional effect in schizophrenic patients with obsessive compulsive symptoms who are taking neuroleptics has not been studied."( Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients.
Benjamin, J; Kaplan, Z; Zohar, J, 1993
)
2.45
"Clomipramine is a serotonin reuptake blocker which produces an increased rate of firing in lateral septal neurons of the rat. "( Clomipramine enhances the excitatory actions of dorsal raphe nucleus stimulation in lateral septal neurons in the rat.
Contreras, CM; Marván, ML; Muñoz-Méndez, A; Ramirez-Morales, A, 1993
)
3.17
"Clomipramine proved to be a useful treatment of depression in patients with probable AD."( A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease.
Chemerinski, E; Leiguarda, R; Petracca, G; Starkstein, SE; Tesón, A, 1996
)
1.28
"Clomipramine is a tricyclic antidepressant that has been recommended for the treatment of canine compulsive disorder. "( The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine.
Ball, RO; Conlon, PD; Hewson, CJ; Luescher, UA, 1998
)
2.05
"Clomipramine is a tricyclic antidepressant drug with a high affinity for the serotonin (5-HT) uptake site or transporter. "( Chronic clomipramine alters presynaptic 5-HT(1B) and postsynaptic 5-HT(1A) receptor sensitivity in rat hypothalamus and hippocampus, respectively.
Dremencov, E; Garcia, F; Gur, E; Lerer, B; Newman, ME; Van de Kar, LD, 2000
)
2.18
"Clomipramine (CMI) is a typical tricyclic antidepressant with a wide clinical spectrum, being used in major depressive, panic and obsessive-compulsive disorders. "( Simultaneous determination of clomipramine and its desmethyl and hydroxy metabolites in plasma of patients by high-performance liquid chromatography after solid-phase extraction.
Bareggi, SR; Bellodi, L; Mundo, E; Pirola, R, 2002
)
2.05
"Clomipramine used alone is an affective analgesic against organic pain due to a lesion of the peripheral nervous system, in particular post-herpetic pain. "( [The treatment of organic pain of the peripheral nervous system using clomipramine. 30 cases (author's transl)].
Castaigne, P; Laplane, D; Morales, R, 1979
)
1.94
"Clomipramine is a tricyclic antidepressant with a strong potentiating effect on central 5-HT."( New evidence of serotonin-deficient depressions.
Van Praag, HM, 1977
)
0.98
"As clomipramine is an antidepressant, this may seem to be an anomaly but it is suggested that depression is secondary to agitation and tension which are recognised side-effects of clomipramine."( Depressive reactions in the course of clomipramine therapy used in the treatment of obsessional conditions.
Capstick, N, 1975
)
1.04
"Clomipramine is a tricyclic which exerts its main actions on serotonergic receptors, and long-term treatment with this antidepressant produced a selective increased firing rate in lateral septal neurons, but not in cortical neurons."( Cortical and septal responses to dorsal raphe nucleus stimulation in the rat: long-term clomipramine actions.
Contreras, CM; Marván, ML; Muñoz-Méndez, A; Ramírez-Morales, A,
)
1.07
"Clomipramine is a chlorinated tricyclic antidepressant commonly used in the treatment of depression (1). "( Toxic neonatal effects following maternal clomipramine therapy.
Katz, EZ; Koren, G; Pastuszak, A; Schimmell, MS; Shaag, Y, 1991
)
1.99
"Clomipramine is a newly marketed tricyclic antidepressant drug prescribed for obsessive-compulsive disorder (OCD). "( Clomipramine for obsessive-compulsive disorder: prescribing guidelines.
James, WA; Lippmann, SB, 1991
)
3.17
"Clomipramine is a tricyclic antidepressant medication widely used in Western Europe. "( Clinical pharmacokinetics of clomipramine.
Balant, LP; Balant-Gorgia, AE; Gex-Fabry, M, 1991
)
2.02
"Clomipramine hydrochloride is a welcome new agent for the treatment of obsessive-compulsive disorder."( Clomipramine: an antiobsessional tricyclic antidepressant.
Austin, LS; Davis, SK; Peters, MD, 1990
)
2.44
"Clomipramine is a potent serotonin reuptake blocker that decreases the symptoms of obsessive-compulsive disorder (OCD). "( Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
Hill, JL; Insel, TR; Murphy, DL; Zohar, J; Zohar-Kadouch, RC, 1988
)
1.95

Effects

Clomipramine has been found to be effective in the treatment of obsessive compulsive disorder (OCD) in nine placebo controlled studies. Other conventional antidepressants lacking 5-HT reuptake inhibiting properties do not appear to beeffective. Clomiprams have been found to enhance the GH and prolactin responses to IV l-TRP after only 2 h.

ExcerptReferenceRelevance
"Clomipramine which has a stimulating effect on oxygen metabolism should be kept in reserve for the chronic phase of prolonged coma."( [Prolonged traumatic and vascular coma: prognostic and therapeutic indications based on hemodynamic and metabolic studies].
Baldy-Moulinier, M; Escuret, E; Frèrebeau, P; Passouant, P; Roquefeuil, B, 1976
)
0.98
"Clomipramine (CLO) has been found to modify the evolution of the experimental infection."( In vitro and in vivo drug combination for the treatment of Trypanosoma cruzi infection: A multivariate approach.
Báez, AL; Bazán, PC; Bustamante, JM; Lo Presti, MS; Nakamura, CV; Paglini-Oliva, P; Rivarola, HW; Rodrigues, JHS; Strauss, M, 2018
)
1.2
"Clomipramine and the SSRIs have been found to be effective across the range of symptoms, both in acute and longer-term studies."( Evidence-based pharmacotherapy of obsessive-compulsive disorder.
Fineberg, NA; Gale, TM, 2005
)
1.05
"If clomipramine or citalopram have been used, an appropriate strategy consists in giving the same drug intravenously."( Management of treatment resistant obsessive-compulsive disorder. Algorithms for pharmacotherapy.
Albert, U; Bergesio, C; Bogetto, F; Maina, G; Pessina, E, 2002
)
0.83
"Clomipramine which has a stimulating effect on oxygen metabolism should be kept in reserve for the chronic phase of prolonged coma."( [Prolonged traumatic and vascular coma: prognostic and therapeutic indications based on hemodynamic and metabolic studies].
Baldy-Moulinier, M; Escuret, E; Frèrebeau, P; Passouant, P; Roquefeuil, B, 1976
)
0.98
"Clomipramine has been prescribed in Europe and Canada for 20 years in management of depression."( Clomipramine for obsessive-compulsive disorder: prescribing guidelines.
James, WA; Lippmann, SB, 1991
)
2.45
"Clomipramine has been reported to be effective in the treatment of obsessive-compulsive disorder (OCD). "( Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination.
Simeon, JG; Thatte, S; Wiggins, D, 1990
)
1.96
"1. Clomipramine has been found to be effective in the treatment of obsessive compulsive disorder (OCD) in nine placebo controlled studies whereas other conventional antidepressants lacking 5-HT reuptake inhibiting properties do not appear to be effective. "( Early response with clomipramine in obsessive compulsive disorder--a placebo controlled study.
Fineberg, N; Montgomery, DB; Montgomery, SA, 1990
)
1.22
"Clomipramine has shown to be effective in that it induced significant improvement on all rating scales as compared to placebo."( Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo.
Gispen-de Wied, CC; Kahn, RS; Kamerbeek, WD; Verhoeven, WM; Westenberg, HG, 1987
)
1.2
"Clomipramine has been found superior to placebo or other psychoactive drugs in 5 controlled studies."( Antidepressant drugs in anxiety disorders.
Modigh, K, 1987
)
0.99

Actions

Clomipramine increase monoaminergic availability at the synaptic level and also suppresses REM sleep. This property may be of value in treating certain features of narcolepsy.

ExcerptReferenceRelevance
"Clomipramine is known to suppress REM sleep, and this property may be of value in treating certain features of narcolepsy. "( The use of clomipramine as an REM sleep suppressant in narcolepsy.
Chen, CN, 1980
)
2.09
"Clomipramine increase monoaminergic availability at the synaptic level and also suppresses REM sleep."( Behavioral effects of neonatal treatment with clomipramine, scopolamine, and idazoxan in male rats.
Aguilar-Garcia, A; Diaz-Ruiz, O; Velazquez-Moctezuma, J, 1993
)
1.27
"Clomipramine appears to produce some short term benefit with exposure therapy in patients with obsessive compulsive disorder."( Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder.
Benfield, P; McTavish, D, 1990
)
2.44

Treatment

Clomipramine pretreatment significantly counteracted the decrease in labeling of the plasma membranes with lipid raft markers. Treatment also decreased the incidence of "growling" during a mirror image stimulation test, relative to non-test periods (P = 0.242 peri-drug treatment)

ExcerptReferenceRelevance
"Clomipramine pretreatment significantly counteracted the decrease in labeling of the plasma membranes with lipid raft markers (fluorescent cholera toxin B subunit and bodipy-GM1-ganglioside) specifically in the junctional regions of the suspended soleus muscle."( Clomipramine counteracts lipid raft disturbance due to short-term muscle disuse.
Bryndina, IG; Petrov, AM; Sekunov, AV; Shalagina, MN; Zefirov, AL, 2018
)
2.64
"Clomipramine treatment also decreased the incidence of "growling" during a mirror image stimulation test, relative to non-test periods (P < 0.0001 pre-drug treatment; P = 0.242 peri-drug treatment), indicating reduced aggression."( Characterization of multiple pathways modulating aggression in the male clouded leopard (Neofelis nebulosa).
DeCaluwe, HB; Howard, J; Ottinger, MA; Pelican, KM; Wielebnowski, NC, 2016
)
1.16
"Clomipramine-treated animals had shifts in the laterality of monoamines in limbic regions with lower serotonin levels on the right side while vehicle-treated animals had lower serotonin on the left side."( Differences in behavior and monoamine laterality following neonatal clomipramine treatment.
Andersen, SL; Dumont, NL; Teicher, MH, 2002
)
1.27
"Clomipramine treatment was associated with significant decreases in TSH and T3 concentrations."( Elevated thyroid indices in children and adolescents with obsessive-compulsive disorder: effects of clomipramine treatment.
Hanna, GL; McCracken, JT, 2005
)
1.27
"Clomipramine treatment was beneficial."( Post-traumatic spontaneous recurrent hypothermia: a variant of Shapiro's syndrome.
De Bleecker, JL; Hemelsoet, DM, 2007
)
1.06
"Four clomipramine-treated breastfeeding mother-infant pairs were assessed for serum concentrations of clomipramine, N-desmethylclomipramine, and corresponding 8-hydroxymetabolites."( Serum clomipramine and metabolite levels in four nursing mother-infant pairs.
Foglia, JP; Perel, JM; Wisner, KL, 1995
)
1.29
"Clomipramine treatment was subsequently discontinued in two patients (off-on-off design), whereas it was discontinued and then reinstituted in three patients (off-on-off-on design)."( Clomipramine treatment of obsessive compulsive symptomatology in schizophrenic patients.
Benjamin, J; Kaplan, Z; Zohar, J, 1993
)
2.45
"Clomipramine treatment was also associated with improvement in SIB intensity, frequency of stereotypy and compulsions, teacher ratings of stereotypy and social withdrawal, and frequency of staff intervention required for problem behaviors."( Clomipramine treatment for self-injurious behavior of individuals with mental retardation: a double-blind comparison with placebo.
Bodfish, JW; Golden, RN; Lewis, MH; Parker, DE; Powell, SB, 1996
)
2.46
"Clomipramine treated animals showed an enhanced cholinomimetic-induced hypothermia and an increased latency in passive avoidance test."( Effects of neonatal clomipramine on cholinergic receptor sensitivity and passive avoidance behavior in adult rats.
Karanth, KS; Kumar, KB; Prathiba, J, 1995
)
1.34
"Clomipramine treatment significantly augmented mean activity values of wheel running rhythm, as well as delayed its acrophase."( Neonatal clomipramine treatment of Syrian hamsters: effect on the circadian system.
Cardinali, DP; Cutrera, RA; Golombek, DA; Yannielli, PC, 1998
)
1.44
"clomipramine and treated subsequently with oral clomipramine were responders, whereas 0 of 18 patients initially randomized to receive i.v."( Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.
Campeas, R; Davies, S; Fallon, BA; Goetz, D; Klein, DF; Liebowitz, MR; Marshall, R; Schneier, FR, 1998
)
1.4
"Clomipramine treatment was better than placebo (all scales) and running (only Clinical Global Impression)."( Endurance training in panic patients: spiroergometric and clinical effects.
Bandelow, B; Broocks, A; Hillmer-Vogel, U; Meyer, T; Rüther, E, 1998
)
1.02
"Clomipramine-treated hamsters exhibited augmented 5-hydroxyindoleacetic acid/serotonin ratio in hypothalamus and midbrain raphe, while serotonin content decreased in frontal cortex and hypothalamic areas."( Effects of neonatal clomipramine treatment on locomotor activity, anxiety-related behavior and serotonin turnover in Syrian hamsters.
Cardinali, DP; Gregoretti, L; Kargieman, L; Yannielli, PC, 1999
)
1.35
"A clomipramine pretreatment (16 mg kg-1 i.p."( Recovery of dopamine neuronal transporter but lack of change of its mRNA in substantia nigra after inactivation by a new irreversible inhibitor characterized in vitro and ex vivo in the rat.
Bonnet, JJ; Costentin, J; Leblond, B; Régo, JC; Syringas, M, 1999
)
0.86
"Clomipramine treatment had a sustained suppressive effect on the dogs' general activity levels, and a more modest suppressive effect on their attachment-related tendency to want much physical contact with their owners."( Evaluation of clomipramine as an adjunct to behavioural therapy in the treatment of separation-related problems in dogs.
Hsu, Y; Podberscek, AL; Serpell, JA, 1999
)
1.39
"Clomipramine treatment was associated with statistically significant improvement on several measures of obsessive compulsive symptoms."( Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
Barklage, NE; Greist, JH; Gutzmann, LD; Jefferson, JW; March, JS; Rosenfeld, R, 1990
)
2.44
"Clomipramine-treated rats had reduced body weight."( Neurobehavioral teratogenic effects of clomipramine and alpha-methyldopa.
De Boer, S; Louwerse, A; Mirmiran, M; van de Poll, NE; Van Haaren, F,
)
1.12
"Treatment with clomipramine alone allowed five patients to achieve sustained remission (MADRS < or = 8), while three patients were responders (MADRS decrease > or = 50%) and three patients were partial responders (MADRS decrease > 25%)."( Is there a place for tricyclic antidepressants and subsequent augmentation strategies in obtaining remission for patients with treatment resistant depression?
Aubry, JM; Bertschy, G; Bondolfi, G; Gervasoni, N; Gex-Fabry, M, 2009
)
0.69
"Treatment with clomipramine resulted in a decrease of whistling."( Compulsive carnival song whistling following cardiac arrest: a case study.
de Koning, P; Denys, D; Figee, M; Olff, M; Polak, AR; van der Paardt, JW; Vulink, N, 2012
)
0.72
"Drug treatment with clomipramine and, to a lesser extent, with selective serotonin reuptake inhibitors was associated with hypomanic switches in OCD-bipolar patients, especially in those not concomitantly treated with mood stabilizers."( Obsessive-compulsive-bipolar comorbidity: a systematic exploration of clinical features and treatment outcome.
Akiskal, HS; Frare, F; Hantouche, E; Perugi, G; Toni, C; Travierso, MC, 2002
)
0.63
"Treatment with clomipramine was associated with significant improvement after both four and six weeks in measures of obsessions, anxiety, and depression."( Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline.
Alterman, I; Cohen, RM; Insel, TR; Kilts, C; Linnoila, M; Murphy, DL, 1983
)
0.85
"Treatment with clomipramine or clonazepam increased the CCK-like immunoreactivity level in the ventral tegmental area (by 64.4 +/- 28.8% and 105.1 +/- 28.8%, respectively) and in the cingulate cortex (by 30.3 +/- 10.1% and 36.0 +/- 11.8%, respectively) (P < 0.05 or P < 0.01)."( Clomipramine and clonazepam increase cholecystokinin levels in rat ventral tegmental area and limbic regions.
Brodin, E; Brodin, K; Ogren, SO, 1994
)
2.07
"Treatment with clomipramine, along with other psychotropic medications and behavioral modification, suppressed the inappropriate behavior in all dogs; in 2 of the 3 dogs, the condition worsened when clomipramine treatment was withdrawn."( Use of clomipramine to treat ritualistic stereotypic motor behavior in three dogs.
Overall, KL, 1994
)
1.08
"When treated with clomipramine 100 mg daily (plasma level 85 ng/mL), obsessive-compulsive symptoms but not the hallucinations improved significantly, and racing thoughts and grandiosity developed later."( Differential response of psychotic and obsessive symptoms to risperidone in an adolescent.
Dryden-Edwards, RC; Reiss, AL, 1996
)
0.62
"Treatment with clomipramine has been suggested, although most sufferers require only reassurance that the spells are benign in nature."( The exploding head syndrome.
Green, MW, 2001
)
0.65
"Pretreatment with clomipramine alone caused a potentiation of neuroleptic-induced catalepsy."( Inhibition of chlorpromazine-induced catalepsy by the 5-HT-1A ligands pindolol and buspirone in mice.
Futuro-Neto, HA; Pires, JG; Silva, SR, 1990
)
0.6
"Treatment with clomipramine resulted in significantly greater improvement in symptoms than desipramine, as indicated by physicians' ratings of the women's clinical progress on a scale in which lower scores indicate improvement (mean [+/- SD] scores: at base line, 10.0; after desipramine treatment, 8.7 +/- 2.4; after clomipramine treatment, 4.7 +/- 3.1; P = 0.006) and by scores on a trichotillomania-impairment scale, in which higher scores indicate greater impairment (at base line, 6.8 +/- 1.7; after desipramine treatment, 6.2 +/- 1.7; after clomipramine treatment, 4.2 +/- 2.7; P = 0.03)."( A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling)
Cheslow, DL; Goldberger, EL; Lenane, MC; Leonard, HL; Rapoport, JL; Swedo, SE, 1989
)
0.91
"Treatment with clomipramine, a tricyclic antidepressant, has proved useful for obsessional patients either as an adjunct to behavior therapy or as a primary treatment for patients who are not amenable to behavioral interventions."( Obsessive-compulsive disorder.
Insel, TR, 1985
)
0.61

Toxicity

Adverse events were observed with significantly higher frequency among patients treated with clomipramine, particularly due to anticholinergic side effects. There were more withdrawals due to adverse events in the clomikramine group than in the sertraline group.

ExcerptReferenceRelevance
" The frequency of adverse events in response to fluoxetine was lower than under clomipramine treatment."( [Efficacy and safety of fluoxetine versus clomipramine in ambulatory patients with a depressive syndrome in a clinical trial with private practitioners].
Dossenbach, M; Pakesch, G, 1991
)
0.77
" Different side effect profiles may have a bearing on patient selection."( Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy.
Baer, L; Greist, JH; Jenike, MA, 1990
)
1.72
"At the present time, there is some concern over the haematological adverse effects of antidepressants."( Reliability of data on haematotoxicity of antidepressants. A retrospective assessment of haematological monitoring in clinical studies on tricyclics.
Biscos-Garreau, M; Girard, M,
)
0.13
" Safety was monitored weekly by recording body weight, blood pressure, pulse rate, temperature, physical conditions, laboratory tests, adverse experiences and concomitant medication."( Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders.
Agnoli, A; Manna, V; Martucci, N, 1989
)
0.5
" The findings indicate that MPTP (or MPP+) is a substrate for the specific DA reuptake system and may explain, in part, its selective toxic effects on DA neurons."( Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP.
Cohen, O; Globus, M; Melamed, E; Rosenthal, J; Uzzan, A, 1985
)
0.27
"Orthostatic hypotension, the clinically most important side effect in treatment with tricyclic antidepressants, was investigated in a double-blind study with clomipramine and the selective serotonin reuptake inhibitor citalopram given for 5 weeks."( Orthostatic side effects of clomipramine and citalopram during treatment for depression.
Christensen, P; Gram, LF; Kragh-Sørensen, P; Pedersen, OL; Thomsen, HY, 1985
)
0.76
"Although there have been previous reports of decreased sexual capacity as a side effect of antidepressants (1-3), the authors know of no previous records of increased capacity of the type described in the following reports, or of reports of side effects associated with yawning."( Unusual side effects of clomipramine associated with yawning.
Forsythe, RG; Kapkin, IA; McLean, JD, 1983
)
0.57
" EEG, ECG, and laboratory parameters and adverse effects reported by the patients, as well as global clinical improvement, were assessed."( Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
Härtter, S; Hiemke, C; Leal, M; Szegedi, A; Wetzel, H, 1996
)
0.59
"Early adverse effects of a drug may be a manifestation of individual differences in drug metabolism or of different pathologic processes."( Relationship between early side effects and therapeutic effects of clomipramine therapy in obsessive-compulsive disorder.
Ackerman, DL; Bystritsky, A; Greenland, S; Katz, RJ, 1996
)
0.53
" A total of 53 patients (49%) completed the 26-week study period; 21% (11/52) of the patients in the milnacipran group and 38% (21/55) of the patients in the clomipramine group discontinued their medication prematurely due to adverse events, whereas 19% (10/52) of those on milnacipran and 7% (4/55) of those on clomipramine treatment withdrew due to either lack of efficacy or clinical deterioration."( Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
Koponen, H; Leinonen, E; Lepola, U; Mehtonen, OP; Rimon, R, 1997
)
0.74
" Adverse events were observed with significantly higher frequency among patients treated with clomipramine, particularly due to anticholinergic side effects."( The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder.
Dahl, AA; Krüger, MB, 1999
)
0.77
"Differences between the side effect profiles of clomipramine (CMI) and the selective serotonin reuptake inhibitors may be important factors in both treatment outcome and patient selection in obsessive-compulsive disorder (OCD)."( Side effects as predictors of drug response in obsessive-compulsive disorder.
Ackerman, DL; Bystritsky, A; Greenland, S, 1999
)
0.56
" There were more withdrawals due to adverse events in the clomipramine group than in the sertraline group (17% versus 12%)."( A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression.
Blashko, C; Goger, J; Kosolowski, J; Lane, RM; Lépine, JP; Moles, MF; Probst, C; Scharfetter, B, 2000
)
0.79
"From a clinical point of view, orthostatic hypotension is a significant side effect during antidepressant treatment, particularly in the case of tricyclic antidepressants (TCAs)."( Orthostatic side effects of clomipramine and moclobemide during treatment for depression.
Stage, KB, 2005
)
0.62
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Among studies that provided comprehensive adverse event data, safety and tolerability observations in men with PE were generally similar to those observed in other populations; however, with the exception of dapoxetine, known SSRI-class effects (e."( Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation.
McMahon, CG; Porst, H, 2011
)
0.37
"This systematic review of well-controlled clinical trials in PE has demonstrated that while many oral agents, particularly SSRIs, tramadol, and dapoxetine, have proven effective and safe for the treatment of men with PE, few have been evaluated for their effects on the specific elements of the ISSM criteria."( Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation.
McMahon, CG; Porst, H, 2011
)
0.37
" The most commonly reported adverse events were nausea in 15."( Efficacy and Safety of On Demand Clomipramine for the Treatment of Premature Ejaculation: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial.
Choi, JB; Choi, WS; Jeon, JS; Kang, SH; Kim, SW; Kim, YS; Lee, DH, 2019
)
0.8

Pharmacokinetics

Clomipramine is one of the drugs for depression during pregnancy. However, pharmacokinetic data of clomiphamine and its active metabolite desmethylclomipamine in this vulnerable period are lacking.

ExcerptReferenceRelevance
"A series of studies on the pharmacokinetic and pharmacodynamic properties of some tricyclic antidepressants is reviewed."( Treatment of depression with tricyclic drugs--pharmacokinetic and pharmacodynamic aspects.
Asberg, M, 1976
)
0.26
" The pharmacokinetic parameters of both molecules were determined in brain tissue and plasma."( Compared plasma and brain pharmacokinetics of clomipramine and its metabolite demethylclomipramine in two strains of mice (NMRI and CD1).
Advenier, C; Bastide, P; Bulach, C; Cordonnier, P; Duroux, E; Eschalier, A; Fialip, J; Marty, H; Pays, M; Varoquaux, O, 1992
)
0.54
" As a consequence, its pharmacokinetic profile is also similar to that observed for these 2 drugs."( Clinical pharmacokinetics of clomipramine.
Balant, LP; Balant-Gorgia, AE; Gex-Fabry, M, 1991
)
0.57
" The administration procedure was based on the pharmacokinetic parameters of CMI determined in the strain used."( Pharmacokinetic patterns of repeated administration of antidepressants in animals. II. Their relevance in a study of the influence of clomipramine on morphine analgesia in mice.
Civiale, MA; Eschalier, A; Fialip, J; Makambila, MC; Marty, H, 1989
)
0.48
" We propose a means of standardizing the pattern of administration for any particular animal, based on a pharmacokinetic study of the antidepressant [here clomipramine (CMI)] in that animal."( Pharmacokinetic patterns of repeated administration of antidepressants in animals. I. Implications for antinociceptive action of clomipramine in mice.
Bastide, P; Eschalier, A; Fialip, J; Makambila, MC; Marty, H; Varoquaux, O, 1988
)
0.68
"The pharmacokinetic profiles of clomipramine (CMP) and the serial changes of its concentration in specific brain regions were investigated in rats after an acute treatment with intravenous CMP (10 mg/kg)."( A pharmacokinetic study of clomipramine in regions of the brain.
Kido, H; Kishitani, K; Kurachi, M; Kurata, K; Yamaguchi, N, 1986
)
0.85
" No correlation between pharmacokinetic and improvement parameters could be found."( Nonlinear pharmacokinetics of chlorimipramine after infusion and oral administration in patients.
Jungkunz, G; Kuss, HJ, 1986
)
0.27
"The pharmacokinetic profiles for chlorimipramine (CIM) and its demethylated metabolite desmethylchlorimipramine (DCIM) in blood and in specific brain regions were obtained in rats after acute or chronic treatment with 15 mg/kg of the tricyclic antidepressant CIM."( Pharmacokinetics of chlorimipramine and its demethylated metabolite in blood and brain regions of rats treated acutely and chronically with chlorimipramine.
Cooper, TB; Friedman, E, 1983
)
0.27
" The biological half-life of amitriptyline in the myocardium was about 37."( Myocardial pharmacokinetics of amitriptyline and clomipramine in the isolated, perfused rabbit heart.
Nielsen-Kudsk, F; Quist, S, 1980
)
0.52
" Their mean clomipramine half-life was 36 hours and mean plasma clomipramine clearance 73 litres per hour, with a wide range in each case."( Single oral dose pharmacokinetics of clomipramine in depressed patients.
Braithwaite, RA; Dawling, S; McAuley, R; Montgomery, SA, 1980
)
0.91
" For eight hours after a single dose plasma clomipramine levels behaved in accordance with known pharmacokinetic principles but thereafter, whichever the route used, there were substantial oscillations, minimal in the morning, maximal early in the afternoon and falling in the late afternoon, peak levels being reached on the second or third day."( Unusual plasma level oscillations of clomipramine in man: a pharmacokinetic and pharmacodynamic dilemma.
De Cuyper, H; De Zeeuw, RA; Van Praag, HM; Westenberg, HG, 1980
)
0.8
" The response to single doses of these two drugs in healthy subjects highlights the two distinct dispositional processes involved, thus offering pharmacokinetic explanation of the hitherto empirical discrepancy in dosage levels in chronic treatment."( Pharmacokinetics of chlorimipramine, chlorpromazine and their N-dealkylated metabolites in plasma of healthy volunteers after a single oral dose of the parent compounds.
Della Corte, L; Giovannini, MG; Palmi, M; Sgaragli, GP; Valoti, M, 1993
)
0.29
"The pharmacokinetic parameters and the time course of the effect after acute oral administration of yohimbine on salivary secretion in patients treated with tricyclic antidepressants were investigated."( Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants.
Bagheri, H; Berlan, M; Houin, G; Montastruc, JL; Picault, P; Schmitt, L, 1994
)
0.29
" We have investigated the role of the lungs in pharmacokinetic drug interactions between tricyclic antidepressants and SSRIs."( Lung as reservoir for antidepressants in pharmacokinetic drug interactions.
Fukuda, H; Obata, T; Okubo, Y; Sasaki, Y; Sudo, Y; Suhara, T; Suzuki, K; Yoshida, K; Yoshikawa, K, 1998
)
0.3
" Various pharmacokinetic parameters were then determined."( The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine.
Ball, RO; Conlon, PD; Hewson, CJ; Luescher, UA, 1998
)
0.61
" Terminal half-life increased slightly (1."( Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration.
Altmann, BO; King, JN; Maurer, MP; Strehlau, GA, 2000
)
0.63
"Because metabolites play a major role in the clinical response to clomipramine, the objective of the current study was to develop a population model and evaluate its performance to describe the pharmacokinetic profiles of clomipramine (C) and its active metabolites desmethylclomipramine (DC), 8-hydroxy-clomipramine (OHC) and 8-hydroxy-desmethylclomipramine (OHDC)."( Population pharmacokinetics of clomipramine, desmethylclomipramine, and hydroxylated metabolites in patients with depression receiving chronic treatment: model evaluation.
Balant, LP; Bechtel, PR; Bizouard, P; Gex-Fabry, M; Haffen, E; Paintaud, G; Sechter, D, 2000
)
0.83
"In this study, the pharmacokinetic parameters of the sustained-release (SR) dosage form of clomipramine (CMI) were compared with those obtained after the administration of the immediate-release (IR) dosage form."( Pharmacokinetics of a sustained-release dosage form of clomipramine.
Galindo, MC; Herrera, D; Jung, H; Mayet, L, 2000
)
0.77
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
"09 h(-1) from which a mean half-life of 12."( Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats.
Doucet, M; Frank, D; Intorre, L; Lainesse, C; Meucci, V; Soldani, G, 2006
)
0.66
"This study was conducted to confirm an interindividual variability in pharmacokinetic parameters of clomipramine in a large population of cats and to identify potential covariables that would explain the presence of such pharmacokinetic variability after a single dose of Clomicalm."( Effects of physiological covariables on pharmacokinetic parameters of clomipramine in a large population of cats after a single oral administration.
Beaudry, F; Doucet, M; Frank, D; Lainesse, C, 2007
)
0.79
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"Clomipramine pharmacokinetic studies in hyperlipidaemic rats were performed with clomipramine continuous infusion."( Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats.
Fukushima, K; Ito, Y; Kobuchi, S; Shibata, M; Sugioka, N; Takada, K, 2011
)
2.14
" First, CPM pharmacokinetic studies in OS rats were performed using CPM continuous infusion (17."( Effect of oxidative stress on the pharmacokinetics of clomipramine in rats treated with ferric-nitrilotriacetate.
Aoyama, H; Fukushima, K; Ito, Y; Kobuchi, S; Matsuda, T; Sugioka, N; Takada, K, 2011
)
0.62
"Clomipramine is one of the drugs for depression during pregnancy; however, pharmacokinetic data of clomipramine and its active metabolite desmethylclomipramine in this vulnerable period are lacking."( Pharmacokinetics of clomipramine during pregnancy.
de Jong-van de Berg, LT; Proost, JH; Smit, JP; Ter Horst, PG; Vries, MT; Wilffert, B, 2015
)
2.18
" Pharmacokinetic and pharmacogenetic analyses may improve drug therapy."( The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression: a case report.
Altamura, CA; Antoniazzi, S; Bernardi, FF; Cattaneo, D; Cheli, S; Cigliobianco, M; Clementi, E; Falvella, FS; Paoli, RA; Tatulli, A, 2017
)
0.68
" In addition, pharmacological treatments should be maintained for years, so that the clinicians should take into account the pharmacokinetic changes in the long-term, which may be responsible for dangerous side effects or interactions."( Pharmacokinetics of serotonergic drugs: focus on OCD.
Avella, MT; Basile, L; Dell'Osso, L; Marazziti, D; Mucci, F, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
" In the present study, the antinociceptive effects of more selective monoamine reuptake inhibitors administered alone and in combination with mu opioid agonists were evaluated in rhesus monkeys using a warm-water tail-withdrawal assay of thermal nociception."( Antinociceptive effects of monoamine reuptake inhibitors administered alone or in combination with mu opioid agonists in rhesus monkeys.
Gatch, MB; Mello, NK; Negus, SS, 1998
)
0.3
"The present study was to investigate the effect of electroacupuncture (EA) combined with chlorimipramine on the sucrose preference of depressive rats induced by chronic mild stress (CMS)."( Sucrose preference is restored by electro-acupuncture combined with chlorimipramine in the depression-model rats.
Cao, XD; Li, XY; Wu, GC; Yu, J, 2006
)
0.33
" We also examined whether Roman chamomile combined with clomipramine treatment affects hippocampal neurogenesis and serum corticosterone levels."( Roman chamomile inhalation combined with clomipramine treatment improves treatment-resistant depression-like behavior in mice.
Hashikawa, N; Hashikawa-Hobara, N; Ishikawa, R; Otsuka, A, 2019
)
1.03

Bioavailability

The relative bioavailability of clomipramine was determined in two single-blind, single-dose, randomized, crossover studies. Clomipramsine is well absorbed from the gastrointestinal tract, but undergoes an important first-pass metabolism to demethyl-clomipamsine.

ExcerptReferenceRelevance
" Data in adult patients illustrate on the one hand possible causes of variability in plasma levels of haloperidol and, on the other hand, the fact that poor bioavailability is not the cause of lack of response in 'resistant' schizophrenic patients."( Clinical significance of monitoring plasma levels of psychotropic drugs.
Morselli, PL; Zarifian, E, 1979
)
0.26
" This method is suitable for in vivo bioavailability studies of unchanged clomipramine, dehydroimipramine, and imipramine after a single oral dose of as little as 25 mg."( Measurement of clomipramine, N-desmethyl-clomipramine, imipramine, and dehydroimipramine in biological fluids by selective ion monitoring, and pharmacokinetics of clomipramine.
Dubois, JP; Küng, W; Theobald, W; Wirz, B, 1976
)
0.84
" Clomipramine is well absorbed from the gastrointestinal tract, but undergoes an important first-pass metabolism to demethyl-clomipramine which is pharmacologically active and participates in both therapeutic and unwanted effects."( Clinical pharmacokinetics of clomipramine.
Balant, LP; Balant-Gorgia, AE; Gex-Fabry, M, 1991
)
1.48
" The drug is well absorbed from the gastrointestinal tract and undergoes extensive first-pass metabolism."( Clomipramine: an antiobsessional tricyclic antidepressant.
Austin, LS; Davis, SK; Peters, MD, 1990
)
1.72
" Significant first-pass metabolism reduces oral bioavailability to less than 62 percent."( Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder.
Kelly, MW; Myers, CW,
)
1.57
" Although the bioavailability of parenteral clomipramine was greater, there were no significant differences in either efficacy or side effects between the two groups."( Acute antidepressant effect following pulse loading with intravenous and oral clomipramine.
Kupfer, DJ; Nathan, RS; Perel, JM; Pollock, BG, 1989
)
0.77
" Absolute bioavailability was 41."( Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection.
Abernethy, DR; Greenblatt, DJ; Shader, RI, 1984
)
0.27
"The relative bioavailability of clomipramine was determined in two single-blind, single-dose, randomized, crossover studies."( Relative bioavailability of four clomipramine hydrochloride tablet products.
De Vaal, AC; Groenewoud, G; Hundt, HK; Luus, HG; Middle, MV; Mogilnicka, EM; Müller, FO; Schall, R; Swart, KJ, 1996
)
0.86
" On the basis of these considerations, the authors hypothesized that grapefruit juice should inhibit tricyclic antidepressant metabolism and thus increase the bioavailability of these drugs."( [Grapefruit juice as a contraindication? An approach in psychiatry].
Bizouard, P; Regina, W; Reix, I; Sechter, D; Vandel, P; Vandel, S,
)
0.13
" The mean oral bioavailability of clomipramine was 24."( Increased bioavailability of clomipramine after sublingual administration in rats.
Lee, HS; Lee, KC; Yoo, SD; Yoon, BM, 1999
)
0.87
" Values for mean residence time and terminal half-life following oral administration were similar to values obtained following IV administration, and systemic bioavailability was approximately 20% for clomipramine and 140% for desmethylclomipramine, indicating fast absorption of clomipramine from the gastrointestinal tract and extensive first-pass metabolism."( Pharmacokinetics of clomipramine in dogs following single-dose intravenous and oral administration.
Fisch, RD; Hotz, RP; King, JN; Maurer, MP, 2000
)
0.82
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"Simulated pharmacokinetic (PK) studies were done to determine the effect of intrinsic clearance (CL(INT)) on the probability of meeting bioequivalence criteria for extent (AUC) and rate (Cmax) of drug absorption when the absorption rate and fraction absorbed (F) were formulated either to be equivalent or to differ by 25%."( The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.
Jackson, AJ, 2000
)
0.31
" Clomipramine bioavailability was 90%."( Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats.
Doucet, M; Frank, D; Intorre, L; Lainesse, C; Meucci, V; Soldani, G, 2006
)
1.57
"Tricyclic antidepressants (TCAs) are the non-selective amine re-uptake inhibitors, well absorbed from small intestine, cross the blood-brain barrier, distributed in the brain, and are bound to glutathione S-transferase-π (GST-π)."( The inhibition characteristics of human placental glutathione S-transferase-π by tricyclic antidepressants: amitriptyline and clomipramine.
Dalmizrak, O; Kulaksiz-Erkmen, G; Ozer, N, 2011
)
0.58
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Patients showing symptoms of depressive illness were treated in general practice with one of four clomipramine (Anafranil) dosage regimes (25 mg t. or less) Overall mean dosage was 45 mg/day, with eight patients receiving 25 mg or less.

ExcerptRelevanceReference
" A dosing strategy for the combbination of clomipramine and haloperidol is described."( [The treatment of chronic pain symptoms with psychotropic drugs (author's transl)].
Kocher, R, 1976
)
0.52
" A clearcut dosage schedule for in- and out-patients using imipramine (Tofranil) or chlorimipramine (Anafranil) and haloperidol (Haldol) is established."( [The treatment of chronic pain with psychotropic drugs].
Kocher, R, 1978
)
0.26
"The subject of dosage of clomipramine (Anafranil) in depression and in obsessional and phobic disorders is discussed."( Practical considerations on the use of clomipramine (Anafranil) in general practice: an updated review.
Beaumont, G, 1977
)
0.83
"A double blind control comparison on the effects of 50 mg of clomipramine given three times a day and 150 mg of clomipramine in a single bedtime dosage revealed no significant differences in therapeutic efficacy."( Are divided doses of tricyclic antidepressants necessary?
Miller, SI; Schubert, DS, 1978
)
0.5
" infusions of Clomipramine in a high dosage, using a fixed therapy schedule with increasing and decreasing dosage ranging from 250 to 500 mg."( [Treatment of therapy resistant depressions with high dose clomipramine].
Laux, G; Reimer, F, 1979
)
0.86
" As the reciprocal plasma level during multiple dosing is proportional to the clearance of a compound, this parameter was used for linear regression analysis."( Intraindividual similarity in the metabolism of amitriptyline and chlorimipramine in depressed patients.
Asberg, M; Bertilsson, L; Mellström, B; Rollins, D; Sjöqvist, F; Träskman, L, 1979
)
0.26
" The method has a high throughput rate, one technician can assay 200 samples in duplicate in a working week; and it is sufficiently precise, sensitive, and specific for use in routine minitoring of the drug in plasma and for checking patient compliance with dosage regimen."( Determination of tricyclic antidepressant, clomipramine (Anafranil), in plasma by a specific radioimmunoassay procedure.
Read, GF; Riad-Fahmy, D, 1978
)
0.52
" Dosage was 20 mg clomipramine during the first three days of treatment, increasing gradually over the next few weeks to a maximum daily dose of 200 mg clomipramine unless side-effects dictated a lower dose."( Pharmacokinetic studies in obsessional patients.
Luscombe, DK; Marks, IM, 1977
)
0.59
" Dose-response relationships and time course of this effect for the various drugs were determined."( Effects of mazindol, fenfluramine and chlorimipramine on the 5-hydroxytryptamine uptake and storage mechanisms in rat brain: similarities and differences.
Carruba, MO; Mantegazza, P; Picotti, GB; Zambotti, F, 1977
)
0.26
" 3 Clomipramine modified these responses of delta9-THC in that the dose-response curves appeared to be shifted to the right."( Antagonism of the effects on thermoregulation of delta9-tetrahydrocannabinol by clomipramine in the rat.
Fennessy, MR; Taylor, DA, 1978
)
1.11
" No systemic changes of heart frequency and blood pressure were found during the infusions in spite of the high dosage of tricyclic antidepressants given such a short period as 1 hour."( Investigation of the orthostatic reaction after intravenous administration of imipramine, chlorimipramine, and inimpramine-N-oxide.
Bake, B; Dencker, SJ, 1976
)
0.26
" Dosage was 1-3 mg daily."( Effect of flupenthixol on depression with special reference to combination use with tricyclic antidepressants. An uncontrolled pilot study with 45 patients.
Baba, O; Fujiwara, J; Hanaoka, M; Ishino, H; Sasaki, K, 1976
)
0.26
" We have tried to explain the difference in the results of works concerning the aggregability of blood-platelets and psychotropes by problems of dosage and of level of action of these medications and of their metabolites, the effects often oposite for a limit dose, the danger of extrapolating in vivo the results found in vitro, finally the complexity and numerous unknown elements in the working of aggregation of blood-platelets."( [Influence of psychotropic therapy on thrombogenesis and platelet functions. A propos of 4 cases of thromboembolic accidents occurring in patients treated by neuroleptics and antidepressants].
Finance, F; Rohmer, F; Ruh-Bernhardt, D; Singer, L, 1976
)
0.26
" A dosage schedule for in- and outpatients has been established, using imipramine (Tofranil) or chlorimipramine (Anafranil), and haloperidol (Haldol)."( The use of psychotropic drugs in the treatment of chronic, severe pains.
Kocher, R, 1976
)
0.26
" For the remaining 29, a comparison with 29 Caucasian patients treated by clomipramine (the two samples are matched for sex and age, and the variables of weight, dosage and drug association are controlled) shows no significantly higher plasma levels in the Beninese sample."( Clomipramine plasma levels among depressed outpatients in Benin, west Africa: drug compliance and comparison with Caucasian patients.
Bertschy, G; Vandel, S, 1992
)
1.96
" The first of these studies of a flexible dosing design showed that sertraline, given for eight weeks in daily dosages of 50-200 mg, was a safe and effective treatment for OCD, and superior to placebo."( Sertraline in the treatment of obsessive compulsive disorder: two double-blind, placebo-controlled studies.
Chouinard, G, 1992
)
0.28
"The phenomenon occurred in all patients during the first 3 weeks of treatment and disappeared within several days when the tricyclic dosage was reduced or the medication was withdrawn."( Painful ejaculation associated with antidepressants in four patients.
Aizenberg, D; Hermesh, H; Karp, L; Weizman, A; Zemishlany, Z, 1991
)
0.28
" The study was designed as a randomised double-blind parallel study involving 139 patients, comparing the effects of a daily dosage of 20 mg fluoxetine, 40 mg fluoxetine and 50 mg clomipramine."( [Efficacy and safety of fluoxetine versus clomipramine in ambulatory patients with a depressive syndrome in a clinical trial with private practitioners].
Dossenbach, M; Pakesch, G, 1991
)
0.74
"A single dosage of several antidepressants produces an increased rate of firing in lateral septal nuclei of the rat."( Chronic clomipramine increases firing rate in lateral septal nuclei of the rat.
Alcalá-Herrera, V; Contreras, CM; Guzmán-Sáenz, MA; Marván, ML, 1990
)
0.71
"The chemistry, pharmacology, pharmacokinetics, adverse effects, and dosage of clomipramine hydrochloride are described, and clinical studies of the use of clomipramine in treating obsessive-compulsive disorder (OCD), other psychiatric conditions, and chronic pain are reviewed."( Clomipramine: an antiobsessional tricyclic antidepressant.
Austin, LS; Davis, SK; Peters, MD, 1990
)
1.95
" Compared with earlier results obtained with imipramine dosed on the basis of plasma level monitoring, clomipramine and desipramine on fixed doses appeared less efficacious whereas the side effect profiles were the same."( Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study.
Beck-Nielsen, H; Brøsen, K; Gram, LF; Grodum, E; Sindrup, SH; Skjold, T, 1990
)
1.94
" Gangliosides, which had no effect per se, showed a clear dose-response relationship in enhancing the anti-immobility effect of desipramine."( Gangliosides enhance the anti-immobility response elicited by several antidepressant treatments in mice.
Basso, AM; Córdoba, NE; Molina, VA; Orsingher, OA, 1990
)
0.28
" Potential implications of the proposed model-based approach include adaptation of the dosage regimen to individual characteristics at the very beginning of antidepressant therapy, and early detection of patients with impaired metabolising capacities."( Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data.
Balant, LP; Balant-Gorgia, AE; Garrone, G; Gex-Fabry, M, 1990
)
1.72
" A tapering schedule was carried out during a 12-day stay in the hospital in which the diazepam dosage was reduced by a fixed quantity every day, corresponding to about ten percent of the initial dosage."( Panic attacks and major depression after discontinuation of long-term diazepam abuse.
Magni, G; Schifano, F, 1989
)
0.28
"A double-blind, randomized trial of oral vs intravenous clomipramine hydrochloride pulse-loading dosing regimens was conducted."( Acute antidepressant effect following pulse loading with intravenous and oral clomipramine.
Kupfer, DJ; Nathan, RS; Perel, JM; Pollock, BG, 1989
)
0.75
" Overall mean dosage was 45 mg/day, with eight patients receiving clomipramine 25 mg or less."( Panic attacks and agoraphobia: low dose clomipramine treatment.
Codner, S; Cohen, L; Gladic, D; Gloger, S; Grunhaus, L; O'Ryan, F, 1989
)
0.78
" Dosage ranged from 600 to 2,400 mg/day for fengabine and 50 to 200 mg/day for TCAs."( Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics.
Garreau, M; Magni, G; Orofiamma, B; Palminteri, R, 1989
)
0.28
" All patients were markedly improved when the daily dosage of the antidepressant was reduced with a simultaneous decrease of the blood concentrations."( High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data.
Balant, LP; Balant-Gorgia, AE; Garrone, G, 1989
)
0.54
" The study was conducted over a period of 28 days and the dosage of each substance, after being gradually increased, was stabilized at 150 mg."( CGP 12.103 A versus clomipramine in the treatment of depressed inpatients--results of a double-blind study.
Binz, U; Hole, G; Steiner, B; Wendt, G; Wolfersdorf, M, 1988
)
0.6
" Twelve weeks later, amitriptyline was replaced by clomipramine (150 mg/day), the dosage of which was increased to 225 mg/day three weeks later."( [Rapid response of a disorder to the addition of lithium carbonate: panic resistant to tricyclic antidepressants].
Cournoyer, J, 1986
)
0.52
" Under this dosage range, full erections occurred during the later hours of sleep in association with the delayed REM periods."( Effects of clomipramine on sleep EEG and nocturnal penile tumescence: a long-term study in a healthy man.
Steiger, A, 1988
)
0.66
" The results of the therapeutic with Clomipramine at low dosage (40 mg) objective a complete removal of panic attacks in 21."( [Panic disorder in general medicine. Epidemiological data and treatment with clomipramine].
Rouillon, F,
)
0.63
"The incidence of potentially toxic serum levels (greater than or equal to 400 ng/ml) was analyzed in a group of 196 monitored patients on a standard dosage regimen (75-225 mg/day) of several antidepressants: imipramine, amitriptyline, nortriptyline, maprotiline and clomipramine."( High levels of tricyclic antidepressants in conventional therapy: determinant factors.
Domínguez-Gil, A; Fernández de Gatta, MM; García, MJ; Gutierrez, JR; Tamayo, M, 1988
)
0.45
" The study medication was prescribed on the basis of weekly increments to a maximum of 300 mg/d, with a mean dosage at week 8 in the clomipramine hydrochloride group of 82."( Clomipramine treatment of agoraphobic women. An eight-week controlled trial.
Johnston, DG; Troyer, IE; Whitsett, SF, 1988
)
1.92
"In a double-blind study on 38 unselected depressive inpatients (19 per group) suffering from endogenous and psychogenic depression, oxaprotiline, a new tetracyclic compound, a hydroxylized maprotiline with a highly selective norepinephrine reuptake inhibition, was compared with clomipramine over a period of 28 days in a daily dosage of 150 mg."( Double-blind study of oxaprotiline versus clomipramine in the treatment of depressive inpatients.
Binz, U; Hole, G; Metzger, R; Wendt, G; Wolfersdorf, M, 1987
)
0.71
"001), indicating a less dose-response in the latter."( A relationship between clomipramine brain concentration and its effect on serotonin metabolism.
Kido, H; Kishitani, K; Kurachi, M; Kurata, K; Yamaguchi, N, 1988
)
0.59
" Doubling of the dosage leads to 3 fold chlorimipramine and 4 fold desmethylchlorimipramine concentrations."( Nonlinear pharmacokinetics of chlorimipramine after infusion and oral administration in patients.
Jungkunz, G; Kuss, HJ, 1986
)
0.27
" Patients were allocated at random to receive clomipramine 75 mg once daily as either the sustained-release or conventional formulation for 11 weeks following a 1-week dosage build-up period."( Efficacy and tolerability of sustained-release clomipramine (Anafranil SR) in the treatment of phobias: a comparison with the conventional formulation of clomipramine (Anafranil).
Allsopp, LF; Brodie, NH; Deering, RB; Huitson, A, 1985
)
0.78
" These responses allowed the construction of dose-response curves."( Effects of chlorpromazine and the antidepressant drugs amitriptyline, clomipramine and mianserin on the Ca-depleted rat uterus.
Anselmi, E; Sevilla, E; Villar, A, 1985
)
0.5
"The sensitivity of neurones in the cingulate cortex of the rat to iontophoretically applied substance P (SP) was tested one hour after a single dose of various antidepressant drugs and also 1 day following the termination of a chronic dosing schedule (14 once daily injections) of the same agents."( An increase in sensitivity of rat cingulate cortical neurones to substance P occurs following withdrawal of chronic administration of antidepressant drugs.
Jones, RS; Olpe, HR, 1984
)
0.27
" A dose-response relationship (5-100 mg/kg) for the hypothermic effect of delta 9-THC was seen."( The mechanism of action of delta 9-tetrahydrocannabinol on body temperature in mice.
Davies, JA; Graham, JD, 1980
)
0.26
" Patients were allocated at random to receive one or other of the trial drugs over a period of 12 weeks and dosage was adjusted to need."( Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice.
Allsopp, LF; Cooper, GL; Poole, PH, 1984
)
1.71
" Thirty-two patients with mixed depression received one or the other drug at the same daily dosage of 150 mg."( A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine.
Dick, P; Ferrero, E, 1983
)
0.27
" In the first study the effects of a single daily dosage of between 100 and 300 mg of fluvoxamine were compared with those of chlorimipramine at a dosage of 50-150 mg daily in 43 out-patients with endogenous depression."( Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing.
De Wilde, JE; Mertens, C; Wakelin, JS, 1983
)
0.27
" In the present study we determined the time-course and dose-response effects of 6-MeO-THbetaC for blockade of AGS."( Effects of 6-methoxy-1,2,3,4-tetrahydro-beta-carboline (6-MeO-THbetaC) on audiogenic seizures in DBA/2J mice.
Buckholtz, NS; Sparks, DL, 1980
)
0.26
" dosage was maintained between 150 and 300 mg per day."( Fluvoxamine maleate, a serotonergic antidepressant; a comparison with chlorimipramine.
Block, BA; Coleman, BS, 1982
)
0.26
" Administration of chlorimipramine in clinical dosage caused a complete disappearance of the 3H-mepyramine affinity for its receptor in the occipital cortex."( 3H-mepyramine binding in various regions of rat brain following chronic treatment with different classes of antidepressant drugs.
Dupont, A; Merand, Y; Savard, P, 1982
)
0.26
" In contrast, in 7 other patients receiving a dosage increasing to 150 mg per day at Day 7, mean plasma levels of C1 and DMC1 continued to rise during the entire treatment period."( Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response.
Allers, G; Jounet, JM; Vandel, B; Vandel, S; Volmat, R, 1982
)
0.52
" The third patient manipulated dosage times to diminish the orgastic problem."( Sexual dysfunction and clomipramine.
Einarson, TR; Quirk, KC, 1982
)
0.57
" Plasma concentrations of both the parent compound and its metabolite rose with dose and within 7-14 days of constant dosage reached steady states."( Plasma concentrations of clomipramine and desmethylclomipramine in obsessive-compulsive neurosis.
Luscombe, DK; Marks, IM; Mawson, D; Stern, RS; Wright, J, 1980
)
0.56
" Clomipramine was prescribed in weekly increments to a maximum of 300 mg per day, with a mean dosage at week 8 of 94."( Clomipramine treatment and behaviour therapy with agoraphobic women.
Dalby, JT; Johnston, DG; Troyer, IE; Whitsett, SF, 1995
)
2.64
"Two different initial dosing regimens with clomipramine (CMI) were used to compare early response indicators and dose strategies."( Effect of pulse loading with clomipramine on EEG sleep.
Ehlers, CL; Grochocinski, VJ; Kupfer, DJ; Miewald, JM; Perel, JM; Pollock, BG, 1994
)
0.84
"Serum hormone levels of follicle stimulating hormone (FSH), luteotropic hormone (LH), testosterone (T), prolactin (hPRL), estradiol (E2) and GnRH test were carried out in 11 patients after antidepressive therapy with clomipramine at a dosage of 75 mg/day for 3 months."( Andrological findings in young patients under long-term antidepressive therapy with clomipramine.
Koinig, G; Maier, U, 1994
)
0.7
" The response to single doses of these two drugs in healthy subjects highlights the two distinct dispositional processes involved, thus offering pharmacokinetic explanation of the hitherto empirical discrepancy in dosage levels in chronic treatment."( Pharmacokinetics of chlorimipramine, chlorpromazine and their N-dealkylated metabolites in plasma of healthy volunteers after a single oral dose of the parent compounds.
Della Corte, L; Giovannini, MG; Palmi, M; Sgaragli, GP; Valoti, M, 1993
)
0.29
" The patients included were randomized into two groups, receiving either an clomipramine 75 tablet or a placebo tablet for two weeks; the dosage could be increased to two tablets as at D14 if necessary and maintained for the next six weeks."( [Controlled study of treatment of residual depression by clomipramine versus placebo].
Febvre, N; Markabi, S; Phillips, R; Rouillon, F; Vaillant, J,
)
0.61
"Two different initial dosing regimens with clomipramine (CMI) were compared with particular attention to early response indicators."( Early response patterns associated with successful clomipramine treatment.
Bowler, KA; Kupfer, DJ; Miewald, JM; Perel, JM; Pollock, BG, 1993
)
0.8
" In many instances, a knowledge of the drug metabolism status of a patient can be helpful in the selection of a drug and its dosage regimen, and in the prediction of possible drug/drug interactions when two or more drugs have to be administered concomitantly."( Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.
Coutts, RT, 1994
)
0.29
"2% of the total were receiving once-daily dosing of the latter type of medication."( Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications.
Rascati, K,
)
0.35
"9 years) taking either amitriptyline or clomipramine in a daily dosage varying from 50 to 250 mg entered the study after giving informed consent."( Influence of heparin on the assay of amitriptyline, clomipramine, and their metabolites.
Levering, SC; Loonen, AJ; Oostelbos, MC; Toll, PJ, 1996
)
0.81
" Dosage was individually regulated; starting dose was 25 mg/day; increments were 25 mg/day."( A pilot study of clomipramine in young autistic children.
Adams, PB; Armenteros, JL; Campbell, M; Cueva, JE; Sanchez, LE; Small, AM, 1996
)
0.63
"The aim of this study was to investigate whether obsessive-compulsive patients previously treated successfully with clomipramine or fluvoxamine could tolerate reduction of the daily dosage without worsening of the clinical condition."( Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study.
Bareggi, SR; Bellodi, L; Mundo, E; Pirola, R; Smeraldi, E, 1997
)
0.51
" After 3 weeks' treatment the dosage in both groups remained almost constant for the rest of the 6-week treatment phase (mean daily dose: tramadol 250 to 290mg; clomipramine 59."( [Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine].
Göbel, H; Stadler, T, 1997
)
0.71
" After 1 week of dose escalation, there was a fixed dosage regimen of either milnacipran (200 mg daily) or clomipramine (150 mg daily) during weeks 2 to 10, followed by flexible dosing of milnacipran (100, 150 or 200 mg daily) or clomipramine (75, 100 or 150 mg daily) during weeks 11 to 26."( Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression.
Koponen, H; Leinonen, E; Lepola, U; Mehtonen, OP; Rimon, R, 1997
)
0.76
" This was followed by flexible dosing with 200, 150, or 100 mg/day milnacipran or 150, 100 or 75 mg/day clomipramine during weeks 11 to 26."( A double-blind six months comparative study of milnacipran and clomipramine in major depressive disorder.
Den Boer, JA; Steen, A, 1997
)
0.75
" Pharmacologic therapy usually includes clomipramine or antidepressant treatment with selective serotonin reuptake inhibitors, but in dosage ranges higher than those typically used in the treatment of depression."( Recognition and treatment of obsessive-compulsive disorder.
Eddy, MF; Walbroehl, GS, 1998
)
0.57
" It was recommended that all dogs in the study be given clomipramine orally at a dosage of 1 to 2 mg/kg (0."( Description and development of compulsive tail chasing in terriers and response to clomipramine treatment.
Dodman, NH; Moon-Fanelli, AA, 1998
)
0.77
"Of the 18 dogs, 15 were treated with clomipramine within the recommended dosage range, and 3 dogs required treatment at a slightly higher dosage range to control tail chasing."( Description and development of compulsive tail chasing in terriers and response to clomipramine treatment.
Dodman, NH; Moon-Fanelli, AA, 1998
)
0.8
" Gradual dosing patients received 25 mg per day increased to 200 mg per day over 2 weeks and then continued for a mean of 43 days (n=40)."( Pulse loading versus gradual dosing of intravenous clomipramine in obsessive-compulsive disorder.
Koran, LM; Paiva, RS; Pallanti, S; Quercioli, L, 1998
)
0.55
" In addition, 'peak' and 'trough' samples were taken throughout the 28-day dosing period."( The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine.
Ball, RO; Conlon, PD; Hewson, CJ; Luescher, UA, 1998
)
0.61
" In patients with partial response, the dosage should be increased to the maximum by 5-9 weeks."( Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature.
Ellingrod, VL,
)
0.13
"This study was designed to explore the dose-response relationship for clomipramine in patients with panic disorder, with or without agoraphobia."( Comparative effects of low and high doses of clomipramine and placebo in panic disorder: a double-blind controlled study. French University Antidepressant Group.
Caillard, V; Markabi, S; Rouillon, F; Viel, JF, 1999
)
0.8
" Additional research is necessary to determine whether changes in the timing and dosage of the clomipramine administration can extend the benefits of the drug to those with the shortest latencies."( Clomipramine in the treatment of rapid (premature) ejaculation.
de Gouveia Brazao, CA; Rowland, DL; Slob, AK; Strassberg, DS; Tan, P,
)
1.79
"Compared with placebo, clomipramine administered to dogs at the dosage recommended for treatment of separation anxiety did not reduce aggressiveness toward human family members."( Effects of clomipramine hydrochloride on dominance-related aggression in dogs.
Cliff, KD; Hart, BL; Neilson, JC; White, MM, 1999
)
1
" This appeared to be a clear-cut reversed dose-response relationship for both substituted benzamides, being the dose potency 1 mg/kg>5 mg/kg>10 mg/kg."( Effects of acute or chronic administration of substituted benzamides in experimental models of depression in rats.
Arezzi, A; Drago, F; Virzì, A, 2000
)
0.31
"In this open case series, the dose-response relationship of atypical antipsychotic augmentation in the treatment of obsessive compulsive disorder (OCD), and the dose-severity relationship in atypical anti psychotic-induced OC symptoms were examined."( Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
Lapierre, Y; Ramasubbu, R; Ravindran, A, 2000
)
0.31
"Case 1: A linear dose-response relationship between increasing doses of olanzapine and improvement in OC symptoms was observed in an OCD patient resistant to 5-HT reuptake inhibitors."( Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
Lapierre, Y; Ramasubbu, R; Ravindran, A, 2000
)
0.31
"Controlled studies are needed to investigate the dose-response or dose-severity relationships between OCD and atypical antipsychotics."( Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
Lapierre, Y; Ramasubbu, R; Ravindran, A, 2000
)
0.31
" Clinical effects from the medications were measured in relation to and shown to be a function of dosage level."( Therapeutic effects and long-term efficacy of antidepressant medication for persons with developmental disabilities. Behavioral assessment in two cases of treatment-resistant aggression and self-injury.
Blew, P; Luiselli, JK; Thibadeau, S, 2001
)
0.31
"In this study, the pharmacokinetic parameters of the sustained-release (SR) dosage form of clomipramine (CMI) were compared with those obtained after the administration of the immediate-release (IR) dosage form."( Pharmacokinetics of a sustained-release dosage form of clomipramine.
Galindo, MC; Herrera, D; Jung, H; Mayet, L, 2000
)
0.77
" A worsening of ritualistic behavior was noted, and the clomipramine dosage was increased to 150 mg/d over 14 days."( Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine.
Dewan, V; Zerjav-Lacombe, S, 2001
)
0.82
"There was a dose-response effect on ejaculatory latency with increasing levels of clomipramine; 30 mg increased the latency from 25 s to 220 s, a clinically significant increase."( Effective daily treatment with clomipramine in men with premature ejaculation when 25 mg (as required) is ineffective.
De Gouveia Brazao, CA; Koos Slob, A; Rowland, DL, 2001
)
0.82
" Dogs continued medication for at least 1 month after clinical signs disappeared or were acceptably reduced, then withdrawal of medication was attempted by decreasing drug dosage at weekly intervals while behaviour modification continued."( Use of clomipramine in treatment of obsessive-compulsive disorder, separation anxiety and noise phobia in dogs: a preliminary, clinical study.
Lindeman, MJ; Seksel, K, 2001
)
0.77
"80 SD, were treated with clomipramine at a mean dosage of 57."( A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics.
Cavagnini, F; Clemente, A; Ferrari, VM; Laini, V; Lugo, F; Mantero, M; Mauri, MC; Redaelli, G; Ruggiero, GM; Zappulli, D, 2001
)
0.86
" The only significant difference in sexual behavior between those males whose mothers received CLI during pregnancy compared to males from untreated mothers was an increase in the number of intromissions in the highest dosage group."( Chronic oral administration of clomipramine decreases sexual behavior in the male Syrian hamster (Mesocricetus auratus).
Boscarino, BT; Parfitt, DB, 2002
)
0.6
"Patients with a DSM-IV diagnosis of OCD and a Yale-Brown Obsessive Compulsive Scale (YBOCS) score >/= 16 were randomly assigned to receive venlafaxine, 225 to 350 mg/day (26 patients), or clomipramine, 150 to 225 mg/day (47 patients), for 12 weeks, with dosage adjustments according to tolerability and response to treatment."( Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.
Aguglia, E; Albert, U; Bogetto, F; Maina, G, 2002
)
0.83
" The presented patient had a second episode of OCD which was resistant to more than 10 weeks of high dosage clomipramine even though he responded very well during the first episode 4 years earlier and had been off clomipramine for 3 years."( Clomipramine-resistant, fluoxetine-responsive obsessive compulsive disorder: a case report.
Paholpak, S, 2002
)
1.97
"Dogs received clomipramine at a dosage of 2 mg/kg (0."( Use of clomipramine, alprazolam, and behavior modification for treatment of storm phobia in dogs.
Crowell-Davis, SL; Curtis, TM; Parthasarathy, V; Seibert, LM; Sung, W, 2003
)
1.13
"To investigate the relationship between 5-HTT occupancy and a wide range of antidepressant dosing protocols."( High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.
Ichimiya, T; Ikoma, Y; Inoue, M; Okubo, Y; Sudo, Y; Suhara, T; Takano, A; Yasuno, F, 2003
)
0.56
" The heterocyclic agent trazodone significantly inhibited paw oedema by 46 and 41% at 1 and 2h after dosing at the highest dose (40 mg kg(-1)) examined."( Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat.
Abdel-Salam, OM; El-Shenawy, SM; Nofal, SM, 2003
)
0.32
" Gender-specific recommendations for dosing of tricyclic antidepressants may be considered."( Are gender differences important for the clinical effects of antidepressants?
Hildebrandt, MG; Kragh-Soerensen, P; Passchier, J; Stage, KB; Steyerberg, EW, 2003
)
0.32
"To determine the optimal dosage of clomipramine for the treatment of urine spraying in cats."( Determination of the dosage of clomipramine for the treatment of urine spraying in cats.
Crowell-Davis, SL; Harrington, LJ; Heath, SE; King, JN; Seewald, W; Simpson, BS; Steffan, J; Weiss, AB, 2004
)
0.89
" TDM and pharmacogenetic tests are useful tools to improve pharmacotherapy by preventing dose-dependent adverse drug events, optimizing dosage during long-term treatment and identifying ultrarapid metabolizers and malcompliance."( [Therapeutic drug monitoring: A pharmacotherapeutic tool in psychiatry].
Etzensberger, M; Jaquenoud Sirot, E; Stephan, PL, 2006
)
0.33
" Further feline studies are required to assess these findings after multiple dosing of clomipramine and DCMP to allow clinical extrapolation."( Effects of physiological covariables on pharmacokinetic parameters of clomipramine in a large population of cats after a single oral administration.
Beaudry, F; Doucet, M; Frank, D; Lainesse, C, 2007
)
0.8
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" The clinical assessment was carried out at baseline (t0) and at the 4th (t1), 12th (t2), 24th (t3), 36th (t4), and 48th (t5) week by means of the Yale-Brown Obsessive Compulsive Scale, Hamilton Rating Scale for Depression, Clinical Global Impression scale, and the Dosage Record and Treatment Emergent Symptom Scale."( Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.
Carlini, M; Catena Dell'osso, M; Consoli, G; Golia, F; Marazziti, D; Mungai, F; Pfanner, C; Presta, S, 2008
)
0.59
" Since venlafaxine is unavailable here, we supplemented her regular venlafaxine dosage of 37."( Symptoms of delusion: the effects of discontinuation of low-dose venlafaxine.
Kodaka, F; Koga, M; Miyata, H; Nakayama, K, 2009
)
0.35
" Side effects were common and almost half these patients became tolerant, needing higher dosage to control symptoms."( Natural history, symptoms and treatment of the narcoleptic syndrome.
Asselman, P; Baraitser, M; Marsden, CD; Parkes, JD, 1975
)
0.25
"In this investigation the effects of tricyclic drugs on cellular respiration were studied using the anaplastic astrocytoma cell line IPSB-18 by use of a Clark-type oxygen electrode which measured changes in cellular respiration rate (oxygen consumption), in a dose-response assay."( The in vitro effects of tricyclic drugs and dexamethasone on cellular respiration of malignant glioma.
Higgins, SC; Pilkington, GJ, 2010
)
0.36
" Results of this study provide useful information for dosage adjustment of clomipramine in hyperlipidaemia."( Pharmacokinetics of clomipramine, an antidepressant, in poloxamer 407-induced hyperlipidaemic model rats.
Fukushima, K; Ito, Y; Kobuchi, S; Shibata, M; Sugioka, N; Takada, K, 2011
)
0.92
" This article presents an evidence-based discussion of the pharmacodynamic and pharmacokinetic adverse effects of the SSRI-clomipramine combination along with suggestions for dosing and monitoring when the combination is used in OCD."( Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder: benefits and risks.
Andrade, C, 2013
)
0.84
" There was no evidence for a relationship between SSRI dosing and treatment effect, although data were limited."( Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
Bloch, MH; Jakubovski, E; Varigonda, AL, 2016
)
0.65
"To evaluate the adequate therapeutic dosage of clomipramine 15 mg/day and clomipramine 30 mg/day in male patients with premature ejaculation (PE), this study enrolled men aged 20-65 years who met diagnostic criteria for PE including Intravaginal Ejaculation Latency Time (IELT) less than 2 min for at least 75% of their sexual intercourses."( Tolerability and adequate therapeutic dosage of oral clomipramine for the treatment of premature ejaculation: A randomized, double-blind, placebo-controlled, fixed-dose, parallel-grouped clinical study.
Choi, JB; Choi, WS; Kim, CM; Kim, KS; Kim, SJ; Kim, SW; Lee, DH, 2018
)
0.99
" Insulin therapy was practiced, with progressive dosage reduction, until complete cessation of treatment after 13 months."( Second-generation antipsychotic and diabetes mellitus in children and adolescents.
Nurchi, AM; Pinna, AP; Podda, F; Ripoli, C; Tronci, MG; Zanni, R, 2017
)
0.46
" Our groups included a female and male control group that was injected with a saline solution, a female and male group that was injected with a low dosage of clomipramine, and a female and male group of rats that were injected with a high dosage of clomipramine."( Effects of short-term clomipramine on anxiety-like behavior, cellular metabolism, and oxidative stress in primary fibroblast cells of male and female rats.
Jimenez, AG; Ragan, CM; Smith, DM; Winward, JD, 2018
)
0.99
" Rats were chronically dosed with respectively clomipramine, citalopram, or midazolam."( Distribution of clomipramine, citalopram, midazolam, and metabolites in skeletal tissue after chronic dosing in rats.
Cuypers, E; Somers, T; Vandenbosch, M, 2019
)
1.12
"The proposed method was applied successfully for the analysis of the cited drugs in pure and dosage forms."( Non-extractive spectrophotometric determination of memantine HCl, clomipramine HCl and fluvoxamine maleate in pure form and in pharmaceutical products by ion-pair complex formation with rose bengal.
El-Alfy, W; El-Mammli, MY; Ismaiel, OA; Sayed, RA; Shalaby, A, 2021
)
0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
serotonergic antagonistDrugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
serotonergic drugnull
serotonin uptake inhibitorA compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitorAn EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD+ or NADP+ as acceptor) inhibitor that interferes with the action of trypanothione-disulfide reductase (EC 1.8.1.12).
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
fluorochromeA fluorescent dye used to stain biological specimens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dibenzoazepine
quaternary ammonium saltDerivatives of ammonium compounds, (NH4(+))Y(-), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Clomipramine Metabolism Pathway414

Protein Targets (142)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.28180.003245.467312,589.2998AID2517
RAR-related orphan receptor gammaMus musculus (house mouse)Potency7.49780.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency12.07560.004110.890331.5287AID493106; AID493107
Fumarate hydrataseHomo sapiens (human)Potency34.71200.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency89.12510.031637.5844354.8130AID504865
PPM1D proteinHomo sapiens (human)Potency11.70860.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency25.15270.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency9.83720.000714.592883.7951AID1259369; AID1259392
ThrombopoietinHomo sapiens (human)Potency12.58930.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency24.75800.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743053; AID743054
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.06840.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency26.60320.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency31.03990.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency26.60320.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency27.54040.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency1.82940.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency22.95550.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.22320.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency33.48890.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.88190.000229.305416,493.5996AID743069; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency0.87090.00108.379861.1304AID1645840
polyproteinZika virusPotency34.71200.00308.794948.0869AID1347053
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency30.73120.001024.504861.6448AID743215; AID743227
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency11.88230.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency26.83250.023723.228263.5986AID743223
arylsulfatase AHomo sapiens (human)Potency0.21331.069113.955137.9330AID720538
caspase-3Homo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.78280.035520.977089.1251AID504332
thyroid stimulating hormone receptorHomo sapiens (human)Potency29.84930.001628.015177.1139AID1259385; AID1259395
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency23.914519.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency17.60540.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency61.93150.039147.5451146.8240AID1224845; AID1224896
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency3.43340.00207.533739.8107AID891
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency25.78770.316212.443531.6228AID902
D(1A) dopamine receptorHomo sapiens (human)Potency1.34770.02245.944922.3872AID488982; AID488983
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency3.79330.134610.395030.1313AID1347049
chromobox protein homolog 1Homo sapiens (human)Potency237.78100.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency12.58930.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency13.86500.000323.4451159.6830AID743065; AID743067
mitogen-activated protein kinase 1Homo sapiens (human)Potency25.11890.039816.784239.8107AID995
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency7.36210.00669.809418.4927AID1347050
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency20.40540.00378.618923.2809AID2667; AID2668
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency31.62280.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency16.78890.004611.374133.4983AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency36.12540.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.27830.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.75630.00106.000935.4813AID943; AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency28.37090.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency8.85680.316212.765731.6228AID881
Interferon betaHomo sapiens (human)Potency11.70860.00339.158239.8107AID1347411
Cellular tumor antigen p53Homo sapiens (human)Potency5.30800.002319.595674.0614AID651631
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency8.85680.00638.235039.8107AID881
D(1A) dopamine receptorSus scrofa (pig)Potency26.12160.00378.108123.2809AID2667
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency28.18380.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency0.44671.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
Ataxin-2Homo sapiens (human)Potency14.12540.011912.222168.7989AID588378
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.27831.000012.224831.6228AID885
2,3-bisphosphoglycerate-independent phosphoglycerate mutaseLeishmania major strain FriedlinPotency0.04787.568615.230621.3313AID504548
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency7.56860.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)19.30000.21005.553710.0000AID386625
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)0.03400.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.01800.00000.887110.0000AID625218
Bile salt export pumpHomo sapiens (human)IC50 (µMol)101.80000.11007.190310.0000AID1443980; AID1449628; AID1473738
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)0.07100.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki0.07000.00322.28879.3160AID625207
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)0.24100.00001.23267.7930AID625152
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki0.08600.00000.690210.0000AID625152
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)0.09100.00001.15467.5858AID625154
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki0.01300.00000.79519.1201AID625154
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.00500.00040.629810.0000AID6418
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.00830.00020.667710.0000AID5241
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)0.05300.00010.99178.0000AID625155
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki0.03800.00000.72926.9183AID625155
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.70700.00001.44217.3470AID36031; AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.53000.00010.807410.0000AID625201
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)3.94650.00002.015110.0000AID625249
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)0.09100.00001.403910.0000AID625151
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.02200.00000.59729.1201AID625151
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)0.41300.00000.74728.0000AID625253
D(2) dopamine receptorHomo sapiens (human)Ki0.13800.00000.651810.0000AID625253
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.00500.00040.908610.0000AID6418
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.00830.00010.601710.0000AID5241
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki0.07500.00010.949010.0000AID218673
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.05050.00001.23808.1590AID36031; AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.04600.00020.725710.0000AID625202
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)0.70650.00001.47257.8980AID36031; AID625203
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.20500.00030.483410.0000AID625203
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.00500.00031.38338.4000AID6418
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki5.00000.00010.739610.0000AID203917
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki0.05100.00000.929610.0000AID218807
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)0.17000.00011.01049.9280AID625153
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.03600.00000.54057.7600AID625153
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)1.11300.00031.84739.2250AID625252
D(1A) dopamine receptorHomo sapiens (human)Ki0.55700.00010.836310.0000AID625252
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Ki0.05100.00000.970810.0000AID218807
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Ki0.05100.00000.937510.0000AID218807
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki0.07500.00000.575110.0000AID218673
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)0.06780.00081.541620.0000AID625207; AID773432
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.07000.00031.465610.0000AID625207
Histamine H2 receptorHomo sapiens (human)IC50 (µMol)2.04900.02202.298710.0000AID625270
Histamine H2 receptorHomo sapiens (human)Ki2.01500.00062.197310.0000AID625270
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)0.18000.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.08800.00000.360910.0000AID625200
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)0.06700.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.01900.00000.385510.0000AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)0.03400.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.01800.00010.954910.0000AID625218
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.00500.00051.48357.8000AID6418
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki5.00000.00031.29679.2440AID203917
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)IC50 (µMol)0.00500.00311.73607.8000AID6418
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Ki5.00000.00101.67479.2000AID203917
Trypanothione reductaseTrypanosoma cruziIC50 (µMol)13.75005.80005.80005.8000AID1062976; AID1379743
Trypanothione reductaseTrypanosoma cruziKi6.62500.07605.15297.6000AID1191810; AID1503509; AID343384; AID419686
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)IC50 (µMol)0.00500.00501.79627.8000AID6418
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Ki5.00000.00101.67479.2000AID203917
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.00500.00040.615610.0000AID6418
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki0.00830.00020.590910.0000AID5241
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)IC50 (µMol)0.00500.00501.50894.6000AID6418
Histamine H1 receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00020.00000.32271.2589AID87513
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)0.03500.00010.86458.7096AID625222; AID92822
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.00020.00000.70488.1930AID1245952; AID625222
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)IC50 (µMol)0.00500.00501.42824.6000AID6418
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)IC50 (µMol)0.00500.00501.35984.6000AID6418
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)IC50 (µMol)0.00500.00501.35984.6000AID6418
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)0.08500.00000.44365.1768AID625269
Histamine H1 receptorHomo sapiens (human)Ki0.00980.00000.511010.0000AID625269
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)0.13900.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.04700.00000.602010.0000AID625254
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)IC50 (µMol)0.00500.00021.13514.6000AID6418
Trypanothione reductaseTrypanosoma brucei bruceiIC50 (µMol)3.40001.70003.36675.0000AID1191811
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.23900.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.15200.00030.769310.0000AID625217
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00000.00001.819410.0000AID36031
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.07500.00000.965010.0000AID218673
Histamine H2 receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.72000.00402.15557.2000AID87880
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)0.24500.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.11300.00020.522910.0000AID625221; AID691260
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)IC50 (µMol)19.30002.03005.53139.9000AID386625
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.05600.00000.437510.0000AID65239
Voltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)IC50 (µMol)9.00000.04004.113710.0000AID1850268
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)2.76150.00071.841946.0000AID625256; AID773429
Sodium-dependent dopamine transporter Homo sapiens (human)Ki2.18200.00021.11158.0280AID625256
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)IC50 (µMol)0.00500.00501.35524.6000AID6418
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)1.36200.00030.70285.3660AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.57200.00000.490110.0000AID625223
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)IC50 (µMol)0.00500.00041.17424.6000AID6418
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinBetacoronavirus England 1EC50 (µMol)11.28000.00304.57559.8200AID1804127
Replicase polyprotein 1abBetacoronavirus England 1EC50 (µMol)11.28000.00304.57559.8200AID1804127
Transmembrane protease serine 2Homo sapiens (human)EC50 (µMol)11.28000.00304.51689.8200AID1804127
Procathepsin LHomo sapiens (human)EC50 (µMol)11.28000.00304.48749.8200AID1804127
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusEC50 (µMol)11.28000.00304.61369.8200AID1804127
Replicase polyprotein 1abHuman coronavirus 229EEC50 (µMol)11.28000.00304.61369.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusEC50 (µMol)11.28000.00304.45549.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)11.28000.00304.11059.8200AID1804127
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusEC50 (µMol)11.28000.00304.57559.8200AID1804127
Proteasome subunit alpha type-6Homo sapiens (human)EC50 (µMol)12.40007.80008.85009.9000AID1794859
Angiotensin-converting enzyme 2 Homo sapiens (human)EC50 (µMol)11.28000.00304.57559.8200AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (588)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
gastric acid secretionHistamine H2 receptorHomo sapiens (human)
immune responseHistamine H2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H2 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
regulation of inflammatory responseProteasome subunit alpha type-6Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProteasome subunit alpha type-6Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
modulation of chemical synaptic transmissionVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
response to amyloid-betaVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
chemical synaptic transmissionVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (175)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
histamine receptor activityHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H2 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H2 receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
RNA bindingProteasome subunit alpha type-6Homo sapiens (human)
endopeptidase activityProteasome subunit alpha type-6Homo sapiens (human)
protein bindingProteasome subunit alpha type-6Homo sapiens (human)
purine ribonucleoside triphosphate bindingProteasome subunit alpha type-6Homo sapiens (human)
NF-kappaB bindingProteasome subunit alpha type-6Homo sapiens (human)
amyloid-beta bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
protein bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
ATP bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (116)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
synapseHistamine H2 receptorHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
dendriteHistamine H2 receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
nucleusProteasome subunit alpha type-6Homo sapiens (human)
cytoplasmProteasome subunit alpha type-6Homo sapiens (human)
proteasome complexProteasome subunit alpha type-6Homo sapiens (human)
P-bodyProteasome subunit alpha type-6Homo sapiens (human)
nucleusProteasome subunit alpha type-6Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-6Homo sapiens (human)
cytosolProteasome subunit alpha type-6Homo sapiens (human)
ribosomeProteasome subunit alpha type-6Homo sapiens (human)
nuclear matrixProteasome subunit alpha type-6Homo sapiens (human)
myofibrilProteasome subunit alpha type-6Homo sapiens (human)
sarcomereProteasome subunit alpha type-6Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
synapseVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
neuronal cell bodyVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (338)

Assay IDTitleYearJournalArticle
AID1346501Mouse Kir3.2 (Inwardly rectifying potassium channels)2004Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Oct, Volume: 29, Issue:10
Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
AID1346943Human SERT (Monoamine transporter subfamily)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
AID1346535Mouse Kir3.4 (Inwardly rectifying potassium channels)2004Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Oct, Volume: 29, Issue:10
Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs.
AID1346971Human NET (Monoamine transporter subfamily)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
AID1346963Human DAT (Monoamine transporter subfamily)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1375640Binding affinity to EBOV Mayinga, Zaire, 1976 envelope glycoprotein extracellular domain H613A mutant tagged with His/foldon trimerization sequence from the bacteriophage T4 fibritin at C terminal expressed in HEK293T cells assessed as decrease in melting2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID1847246Antiviral activity against Ebola virus infected in African green monkey assessed as reduction in viral infection incubated for 48 hrs by CellTiter-Glo Luminescent Cell Viability Assay2021European journal of medicinal chemistry, Nov-05, Volume: 223Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.
AID1053264Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative t2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID419686Inhibition of Trypanosoma cruzi trypanothione reductase expressed in Escherichia coli JM109 cells2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase.
AID1379743Inhibition of Trypanosoma cruzi trypanothione reductase expressed in Escherichia coli BL21 (DE3) pre-incubated for 30 mins using TS2 substrate in presence of NADPH by colorimetric microplate assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Synthesis and 2D-QSAR studies of neolignan-based diaryl-tetrahydrofuran and -furan analogues with remarkable activity against Trypanosoma cruzi and assessment of the trypanothione reductase activity.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1245955Displacement of [3H]-nisoxetine from norepinephrine transporter (unknown origin) at 0.1 mM relative to control2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Reengineered tricyclic anti-cancer agents.
AID5241Binding affinity towards 5-hydroxytryptamine 2 receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID112623Compound was tested for antidepressant activity against reserpine induced ptosis in mice after intraperitoneal administration; value ranges from 1.8-4.11989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID309946Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 19.42 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID667263Antidepressant activity in Swiss albino mouse assessed as decrease in immobility time at 30 mg/kg, ip administered 30 mins before test measured for 4 mins of total 6 mins test by forced swim test2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis, antidepressant and antimicrobial activities of some novel stearic acid analogues.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID624659Inhibition of morphine (6-O-glucuronidation) glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID129181Antidepressant activity was measured by the inhibition of tetrabenazine (TBZ) ptosis in mice after ip administration1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Novel tetracyclic spiropiperidines. 1. 3-Aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4'-piperidines] as potential antidepressants.
AID1400236Growth inhibition of Trypanosoma cruzi Tulahuen amastigote forms infected in human THP1 cells after 72 hrs by beta-galactosidase reporter gene assay2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
Synthesis and SAR of new isoxazole-triazole bis-heterocyclic compounds as analogues of natural lignans with antiparasitic activity.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID189474Apparent partition coefficient was measured as histamine releasing activity in rat mast cells.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID23977Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID773429Displacement of [3H]Win35428 from human recombinant DAT over-expressed in CHOK1 cells2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.
AID224550Percent increase of the diameter of the test pupil (% mydriasis) in comparison with that of the control pupil.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID329205Inhibition of L-[3H]Ala uptake at Aquifex aeolicus sodium-coupled leucine transporter2007Nature, Aug-23, Volume: 448, Issue:7156
Antidepressant binding site in a bacterial homologue of neurotransmitter transporters.
AID26296Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID309947Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 25.89 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID309949Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in intraperitoneally dosed mouse after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID540237Phospholipidosis-positive literature compound observed in rat
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID87513Compound tested for its inhibitory activity against Histamine H1 receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1135984Potentiation of 5-HTP-induced head twitches in ip dosed NMRI albino mouse administered 1 hr prior to 5-HTP challenge1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID309938Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 12.94 mM/kg, ip after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID181684Inhibition of uptake of noradrenaline in rat brain hypothalamus1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
3-(4-Piperidinylalkyl)indoles, selective inhibitors of neuronal 5-hydroxytryptamine uptake.
AID222978Antagonism of tetrabenazine-induced ptosis in mice was evaluated after oral administration1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID309934Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 1.62 mM/kg, ip after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID169587Antagonism of tetrabenazine ptosis in rat after oral administration1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
3-(4-Piperidinylalkyl)indoles, selective inhibitors of neuronal 5-hydroxytryptamine uptake.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID25866Protonation constant of the compound.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1211795Dissociation constant, pKa of the compound2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1220558Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1135979Inhibition of noradrenaline transporter in NMRI albino mouse brain assessed as [3H]NA accumulation in hypothalamus after 5 mins1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1053262Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 100 uM by luminometric analysis relative to quinpirol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID256130Antidepressant activity determined by percentage change from control after intraperitoneal administration at 100 mg/kg in mice; n = 62005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
Synthesis and antidepressant activity of some 1,3,5-triphenyl-2-pyrazolines and 3-(2''-hydroxy naphthalen-1''-yl)-1,5-diphenyl-2-pyrazolines.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1647325Neuroprotective activity against OGD-induced hypoxic injury in human SH-SY5Y cells assessed as LDH release at 1 nM to 10 uM incubated under oxygen/glucose deprivation-induced hypoxic medium by LDH assay2020European journal of medicinal chemistry, Feb-01, Volume: 187Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID23965logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1220556Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1211797Intrinsic clearance in cryopreserved human hepatocytes cells assessed per 10'6 cells by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID92822In vivo inhibition of uptake of 5-HT in human platelets1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
3-(4-Piperidinylalkyl)indoles, selective inhibitors of neuronal 5-hydroxytryptamine uptake.
AID1144380Antipsychotic activity in po dosed mouse assessed as change in methamphetamine-induced hyperactivity1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID115597Ability to modify turning behavior of mice after intraperitoneal administration; NT is not tested.1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID1144372Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of serotonin-induced tremor, head movements, abducted limbs and irritability at 50 mg/kg, po treated 1 hr prior to serotonin-challenge1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID679771TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Clomipramine: 100 uM) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID29813Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1144373Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of serotonin-induced tremor, head movements, abducted limbs and irritability at 100 mg/kg, po treated 1 hr prior to serotonin-challenge1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID567857Antifungal activity against Aspergillus niger MTCC 281 after 72 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
AID1863562Antiviral activity against pseudotyped Ebola virus assessed as inhibition of viral entry2022European journal of medicinal chemistry, Oct-05, Volume: 240Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
AID223123Potentiation of 5-hydroxytryptophan-induced head twitch in mice after oral administration1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID23971logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID218807Binding affinity towards alpha-2 adrenergic receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID256119Antidepressant activity determined by duration of immobility after intraperitoneal administration at 100 mg/kg in mice2005Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22
Synthesis and antidepressant activity of some 1,3,5-triphenyl-2-pyrazolines and 3-(2''-hydroxy naphthalen-1''-yl)-1,5-diphenyl-2-pyrazolines.
AID130699In vivo inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices after intraperitoneal administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID343384Inhibition of Trypanosoma cruzi recombinant trypanothione reductase2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID1135985Mydriatic effect in iv dosed NMRI albino mouse assessed as concentration required to increase pupil diameter by 200%1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID87880Inhibitory activity against brain adenylate cyclase Histamine H2 receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1245954Displacement of [3H]-BTCP from dopamine transporter (unknown origin) at 10 mM relative to control2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Reengineered tricyclic anti-cancer agents.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID329208Activity at Aquifex aeolicus sodium-coupled leucine transporter assessed as inhibition of L-[3H]Ala transport at 50 uM2007Nature, Aug-23, Volume: 448, Issue:7156
Antidepressant binding site in a bacterial homologue of neurotransmitter transporters.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID567860Antifungal activity against Penicillium citrinum NCIM 768 after 72 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
AID681116TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID23961logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID643383Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID329206Activity at Aquifex aeolicus sodium-coupled leucine transporter assessed as inhibition of L-[3H]Ala transport at 1 uM2007Nature, Aug-23, Volume: 448, Issue:7156
Antidepressant binding site in a bacterial homologue of neurotransmitter transporters.
AID130700In vivo inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices after intraperitoneal administration1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID309945Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 12.94 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1062976Inhibition of Trypanosoma cruzi trypanothione reductase expressed in Escherichia coli BL21(DE3) assessed as reduction of oxidized trypanothione preincubated for 30 mins measured for 30 mins by spectrophotometric analysis2014European journal of medicinal chemistry, Jan, Volume: 71Synthesis and evaluation of the antiparasitic activity of bis-(arylmethylidene) cycloalkanones.
AID1245953Displacement of [3H]-BTCP from dopamine transporter (unknown origin) at 1 mM relative to control2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Reengineered tricyclic anti-cancer agents.
AID1135982Antidepressant activity in ip dosed NMRI albino mouse assessed as inhibition of [3H]5-HT accumulation in hypothalamus after 0.5 hrs1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID1144374Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of serotonin-induced tremor, head movements, abducted limbs and irritability at 25 mg/kg, po treated 4 hrs prior to serotonin-challenge1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID667264Antidepressant activity in Swiss albino mouse assessed as increase in dopamine level in brain at 30 mg/kg, ip by HPLC analysis2012European journal of medicinal chemistry, Aug, Volume: 54Synthesis, antidepressant and antimicrobial activities of some novel stearic acid analogues.
AID1211792Hepatic clearance in human2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1144376Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of serotonin-induced tremor, head movements, abducted limbs and irritability at 100 mg/kg, po treated 4 hrs prior to serotonin-challenge1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID181683Inhibition of uptake of dopamine (DA) rat brain striatum1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
3-(4-Piperidinylalkyl)indoles, selective inhibitors of neuronal 5-hydroxytryptamine uptake.
AID181517Ability to inhibit the uptake of norepinephrine (NE) by crude synaptosomes from rat whole brain1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthesis and anxiolytic activity of a series of pyrazino[1,2-a][1,4]benzodiazepine derivatives.
AID309944Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 9.71 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID329207Activity at Aquifex aeolicus sodium-coupled leucine transporter assessed as inhibition of L-[3H]Ala transport at 20 uM2007Nature, Aug-23, Volume: 448, Issue:7156
Antidepressant binding site in a bacterial homologue of neurotransmitter transporters.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1053266Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 100 uM after 30 mins by HTRF assay relative to SKF812972013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1503509Inhibition of Trypanosoma cruzi trypanothione reductase assessed as reduction in NADPH consumption using varying levels of trypanothione disulfide as substrate by Lineweaver-Burk plot analysis2017European journal of medicinal chemistry, Dec-01, Volume: 141Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity.
AID309941Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 3.24 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1070215Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1245952Displacement of [3H]-imipramine from human serotonin transporter expressed in HEK293 cells after 30 mins by liquid scintillation counting analysis2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Reengineered tricyclic anti-cancer agents.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID1135983Antidepressant activity in ip dosed NMRI albino mouse assessed as inhibition of [3H]DA accumulation in hypothalamus after 0.5 hrs1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID1135981Antidepressant activity in ip dosed NMRI albino mouse assessed as inhibition of [3H]NA accumulation in hypothalamus after 0.5 hrs1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID309936Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 4.86 mM/kg, ip after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID23708Partition coefficient (logP)1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID22538Half life period is estimated1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID567858Antifungal activity against Aspergillus flavus MTCC 277 after 72 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1135986Acute toxicity in iv dosed NMRI albino mouse assessed as lethality up to 24 hrs1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID386625Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1191821Inhibition of yeast glutathione reductase assessed as reduction of glutathione disulfide up to 250 uM by spectrophotometrically2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Dibenzosuberyl substituted polyamines and analogs of clomipramine as effective inhibitors of trypanothione reductase; molecular docking, and assessment of trypanocidal activities.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1144375Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of serotonin-induced tremor, head movements, abducted limbs and irritability at 50 mg/kg, po treated 4 hrs prior to serotonin-challenge1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID203917Binding affinity towards serotonin S1 receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID15708Plasma clearance for the compound was determined.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID567859Antifungal activity against Monascus purpureus MTCC 369 after 72 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID624658Inhibition of morphine (3-O-glucuronidation) glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID34292Compound was tested for its binding affinity towards brain (Hippocampus) Adenylate cyclase1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID181682Inhibition of uptake of 5-HT in rat brain cortex1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
3-(4-Piperidinylalkyl)indoles, selective inhibitors of neuronal 5-hydroxytryptamine uptake.
AID1053260Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID129282Antidepressant activity was measured by the inhibition of tetrabenazine (TBZ) ptosis in mice after po administration1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Novel tetracyclic spiropiperidines. 1. 3-Aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4'-piperidines] as potential antidepressants.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID103232Anti MDR activity was expressed as MDR ratio or MDR fold reversal in doxorubicin resistant human breast carcinoma tumor cell line MCF-7/DOX1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211794Fraction unbound in blood (not specified)2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID567861Neurotoxicity in rat assessed as impair in motor coordination at after 30 mins by rotarod test (Rvb = 116.50 +/- 1.18 sec)2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
AID26300log P values determined at pH 7.41999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID309950Selectivity ratio of ED50 for 5-HT reuptake in mouse to ED50 for norepinephrine reuptake in mouse2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1135980Inhibition of 5-HT transporter in NMRI albino mouse brain assessed as [3H]5-HT accumulation in hypothalamus after 5 mins1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Antidepressant agents. 9. 3,3-Diphenylcyclobutylamines, a new class of central stimulants.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID309948Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced intraperitoneally dosed mouse head twitch after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1211798Intrinsic clearance in human using well stirred liver model by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID6418Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID547622Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID132666In vitro inhibition of accumulation of [14C]5-HT (5-HT) in mouse brain slices1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID26538log K was measured potentiometrically in Brij35 medium1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1191816Trypanocidal activity against bloodstream form of Trypanosoma brucei assessed as inhibition of trypanosomes after 48 hrs2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Dibenzosuberyl substituted polyamines and analogs of clomipramine as effective inhibitors of trypanothione reductase; molecular docking, and assessment of trypanocidal activities.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID309939Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 25.89 mM/kg, ip after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID132665In vitro inhibition of accumulation of (-)-[3H]Norepinephrine (NA) in mouse brain slices1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis of pyridylallylamines related to zimelidine and their inhibition of neuronal monoamine uptake.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1191810Inhibition of Trypanosoma cruzi trypanothione reductase assessed as reduction of trypanothione disulfide by spectrophotometrically2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Dibenzosuberyl substituted polyamines and analogs of clomipramine as effective inhibitors of trypanothione reductase; molecular docking, and assessment of trypanocidal activities.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID36031Compound was tested for its inhibitory activity against Alpha-1 adrenergic receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1144371Antidepressant activity in pargyline-pretreated mouse assessed as potentiation of serotonin-induced tremor, head movements, abducted limbs and irritability at 25 mg/kg, po treated 1 hr prior to serotonin-challenge1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Novel analogs of tricyclic psychopharmacological agents.
AID214649Natural log of the value in (uM) of inhibition constant was tested against Trypanothione Reductase1997Journal of medicinal chemistry, Jul-18, Volume: 40, Issue:15
A virtual screening approach applied to the search for trypanothione reductase inhibitors.
AID147591Compound was tested for its inhibitory activity against Noradrenaline receptor1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID309943Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 6.47 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID221731Ability to kill 50% of the animals after 24h, when administered perorally1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID603955In-vivo blood to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID309940Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 1.62 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1375644Antiviral activity against Ebolavirus expressing eGFP infected in African green monkey Vero E6 cells assessed as inhibition of viral replication after 48 hrs by spectrofluorometric method2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID1245889Cytotoxicity against human NCI-H1650 cells assessed as growth inhibition after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Reengineered tricyclic anti-cancer agents.
AID1129361Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1220559Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID65239Binding affinity towards Dopamine receptor D21987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID309937Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 6.47 mM/kg, ip after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1220557Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1375643Antiviral activity against Ebolavirus like particle harboring full length EBOV Zaire wt/GIN/2014/ Kissidougou-C15 envelope glycoprotein and Influenzae virus envelope assessed as inhibition of viral infection in MDCK-SIAT1 cells after 48 hrs by e-GFP-based2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID1207631Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1375645Antiviral activity against Ebolavirus like particle harboring EBOV VP40 assessed as inhibition of viral infection in human HeLa cells preincubated with host cells for 1 hrs followed by viral inoculation by beta-lactamse reporter assay2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID567855Antidepressant activity in Albino rat assessed as immobility time at 20 mg/kg, ip by forced swimming test (Rvb = 112.4 +/- 2.88 sec)2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
AID1220555Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1375641Binding affinity to EBOV Mayinga, Zaire, 1976 envelope glycoprotein extracellular domain H613A mutant tagged with His/foldon trimerization sequence from the bacteriophage T4 fibritin at C terminal expressed in HEK293T cells at pH 5.2 by SYPRO orange dye-b2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID1765968Inhibition of Leishmania Trypanothione reductase
AID1245892Cell cycle arrest in human NCI-H1650 cells assessed as accumulation at sub-G1 phase at 1 to 40 uM by propidium iodide staining-based flow cytometric analysis2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Reengineered tricyclic anti-cancer agents.
AID309942Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 4.86 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1220560Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1191811Inhibition of recombinant Trypanosoma brucei brucei strain S427 trypanothione reductase assessed as reduction of trypanothione disulphide by 412 nm assay2015Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5
Dibenzosuberyl substituted polyamines and analogs of clomipramine as effective inhibitors of trypanothione reductase; molecular docking, and assessment of trypanocidal activities.
AID1245970Inhibition of Nav1.5 channel (unknown origin) expressed in HEK293 cells at 0.1 to 10 mM by patch clamp assay2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Reengineered tricyclic anti-cancer agents.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID131009Compound was tested for potentiation of 5-HTP in mouse after subcutaneous administration1980Journal of medicinal chemistry, Dec, Volume: 23, Issue:12
3-(4-Piperidinylalkyl)indoles, selective inhibitors of neuronal 5-hydroxytryptamine uptake.
AID547804Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID22345Therapeutic plasma levels for the compound was evaluated.1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID218673Binding affinity towards alpha-1 adrenergic receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1245957Displacement of [3H]-nisoxetine from norepinephrine transporter (unknown origin) at 10 mM relative to control2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Reengineered tricyclic anti-cancer agents.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID23963logD (measured by HPLC) (as log k')1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID329204Inhibition of L-[3H]Leu uptake at Aquifex aeolicus sodium-coupled leucine transporter2007Nature, Aug-23, Volume: 448, Issue:7156
Antidepressant binding site in a bacterial homologue of neurotransmitter transporters.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID114245Serotonergic activity by measuring the potentiation of 5-hydroxy tryptophan in mice upon ip administration; value ranges from 3-7.9.1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID773432Displacement of [3H]Nisoxetine from human recombinant NET over-expressed in dog MDCK cells2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.
AID691260Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells after 1.5 hrs by liquid scintillation counting2012Journal of medicinal chemistry, Jun-28, Volume: 55, Issue:12
Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.
AID223128Ability to kill 50% of the animals (administered orally), after sublethal dose of yohimbine (25 mg/Kg) when given subcutaneously.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID34291Compound was evaluated for in vitro inhibition of histamine activated adenylate cyclase in guinea pig cerebral cortex1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthesis and anxiolytic activity of a series of pyrazino[1,2-a][1,4]benzodiazepine derivatives.
AID1211791Fraction unbound in human hepatocytes2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID178456Antidepressant activity was measured by the potentiation of head twitching induced by 5-hydroxy-tryptophan in pargyline-pretreated rats after ip administration1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Novel tetracyclic spiropiperidines. 1. 3-Aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4'-piperidines] as potential antidepressants.
AID1245956Displacement of [3H]-nisoxetine from norepinephrine transporter (unknown origin) at 1 mM relative to control2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Reengineered tricyclic anti-cancer agents.
AID781329pKa (acid-base dissociation constant) as determined by other workers2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID547621Cytotoxicity against BESM cells after 88 hrs by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID177104ED50 value expresses the inhibition of serotonin reuptake in rat.1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Piperazinylquinoxalines with central serotoninmimetic activity.
AID34293Compound was tested for its binding affinity towards brain (neocortex) Adenylate cyclase1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID309935Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 3.24 mM/kg, ip after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID181518Ability to inhibit the uptake of serotonin (5-HT) by crude synaptosomes from rat whole brain1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthesis and anxiolytic activity of a series of pyrazino[1,2-a][1,4]benzodiazepine derivatives.
AID1850268Inhibition of endogenous human CaV2.2 in human SH-SY5Y cells in presence of nifedipine by Calcium 4 dye based calcium influx fluorescence-imaging assay2022RSC medicinal chemistry, Feb-23, Volume: 13, Issue:2
Inhibition of N-type calcium ion channels by tricyclic antidepressants - experimental and theoretical justification for their use for neuropathic pain.
AID1220554Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID22432Volume of distribution in the plasma fluid was determined1999Journal of medicinal chemistry, Aug-12, Volume: 42, Issue:16
Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID781330pKa (acid-base dissociation constant) as determined by potentiometric titration2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1211796Intrinsic clearance in cryopreserved human HepaRG cells assessed per 10'6 cells by LC-MS/MS method2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
AID186205Log (1/ED50) was measured as histamine releasing activity in rat mast cells; log(1/ED50*10e-3).1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Octanol-physiological buffer distribution coefficients of lipophilic amines by reversed-phase high-performance liquid chromatography and their correlation with biological activity.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID1794859Proteasome Activity Assay from Article 10.1021/acschembio.7b00489: \\Small Molecule Enhancement of 20S Proteasome Activity Targets Intrinsically Disordered Proteins.\\2017ACS chemical biology, 09-15, Volume: 12, Issue:9
Small Molecule Enhancement of 20S Proteasome Activity Targets Intrinsically Disordered Proteins.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,727)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901048 (38.43)18.7374
1990's844 (30.95)18.2507
2000's484 (17.75)29.6817
2010's299 (10.96)24.3611
2020's52 (1.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 97.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index97.87 (24.57)
Research Supply Index8.15 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index190.02 (26.88)
Search Engine Supply Index2.08 (0.95)

This Compound (97.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials541 (18.47%)5.53%
Trials0 (0.00%)5.53%
Reviews263 (8.98%)6.00%
Reviews0 (0.00%)6.00%
Case Studies492 (16.80%)4.05%
Case Studies0 (0.00%)4.05%
Observational1 (0.03%)0.25%
Observational0 (0.00%)0.25%
Other1,632 (55.72%)84.16%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-blind, Placebo-controlled, Fixed Dose, Parallel Grouped Clinical Study to Evaluate the Tolerability and to Determine the Adequate Dosage of PED-1 and PED-2 in Male Patients With Premature Ejaculation [NCT01203202]Phase 2104 participants (Actual)Interventional2010-09-30Completed
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial [NCT01305707]Phase 4104 participants (Actual)Interventional2009-07-31Terminated(stopped due to Difficulties in recruiting)
Efficacy of Antidepressants in Chronic Back Pain [NCT00964886]Phase 2142 participants (Actual)Interventional2010-01-31Completed
Assessment of PACAP-BDNF Signaling System Involvement in Etiology and Treatment of Major Depression [NCT00944996]100 participants (Actual)Interventional2009-06-30Completed
Comparative, Randomized, 3-way Crossover Bioavailability Study of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules In Health Adult Males Under Fed and Fasted Conditions [NCT00913952]Phase 118 participants (Actual)Interventional1994-04-30Completed
Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial. [NCT00564564]Phase 421 participants (Actual)Interventional2006-01-31Completed
A Randomized, Open-labeled, 6-sequence, 3-period, 3-treatment Crossover Study to Evaluate the Effect of Co-administration of Clomipramine HCl (Condencia Tab.) 15mg and Sildenafil Citrate (Viagra Tab.) 100mg on the Safety and Pharmacokinetic/Pharmacodynami [NCT02028598]Phase 130 participants (Actual)Interventional2014-01-31Completed
Comparative, Randomized, 2-way Crossover Bioavailability Study of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules In Health Adult Males Under Fasted Conditions [NCT00913783]Phase 136 participants (Actual)Interventional1992-11-30Completed
A Randomized, Double-blind, Placebo-controlled, Fixed Dose, Parallel Grouped, Multi-center Clinical Study to Evaluate the Safety and Efficacy of PED-1 in Male Patients With Premature Ejaculation [NCT01439984]Phase 3159 participants (Actual)Interventional2011-09-30Completed
Predicting Medication Response in Obsessive Compulsive Disorder [NCT01404871]26 participants (Actual)Interventional2009-04-30Completed
Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study [NCT00466609]Phase 454 participants (Actual)Interventional2007-05-31Completed
Efficacy of Antidepressants in Chronic Back Pain [NCT00018200]Phase 2130 participants (Actual)Interventional1999-04-30Completed
Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study [NCT00254735]Phase 344 participants (Actual)Interventional2002-04-30Completed
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression [NCT01896349]74 participants (Anticipated)Interventional2013-04-30Recruiting
Treatment of Pediatric OCD for SRI Partial Responders [NCT00074815]Phase 3124 participants (Actual)Interventional2003-09-30Completed
[NCT01575158]59 participants (Actual)Interventional1997-10-31Completed
[NCT00004310]Phase 276 participants Interventional1999-10-31Active, not recruiting
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial. [NCT05737511]Phase 480 participants (Anticipated)Interventional2023-12-30Not yet recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00074815 (1) [back to overview]Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
NCT00964886 (2) [back to overview]Intent-toTreat Analysis of Descriptor Differential Scale (DDS) of Pain Intensity
NCT00964886 (2) [back to overview]Roland and Morris Disability Questionnaire

Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

"OCD symptom severity was measured using the CY-BOCS, an interviewer-rated instrument that assess obsessions and compulsions separately on time consumed, distress, interference, degree of resistance, and control; it yields separate severity scores for obsessions and for compulsions (0 - 20), and a composite symptom severity score (0 to 40).~Consistent with signal detection analyses examining the optimal criterion for treatment response, a CY-BOCS reduction of 30% or more from baseline to week 12 was used as the criterion for RESPONSE and was the primary dichotomous outcome measure." (NCT00074815)
Timeframe: Measured at baseline and Week 12.

InterventionProportion of Participants with RESPONSE (Number)
MM + CBT0.69
MM + ICBT0.34
MM Only0.30

[back to top]

Intent-toTreat Analysis of Descriptor Differential Scale (DDS) of Pain Intensity

"The DDS is self-report measure of current pain intensity of chronic back pain. Participants rate pain on a 20 point scale as being greater or less intense relative to 12 adjectival descriptor words which serve as anchors (eg, greater or less than faint, moderate, strong). Scores range from 0 to 20 with higher scores indicating higher pain intensity. The analysis evaluated the 'as randomized' sample at 12 weeks after baseline or last observation carried forward, after co-varying for baseline (pre-treatment) values." (NCT00964886)
Timeframe: 12 weeks after baseline (or last observation carried forward)

Interventionunits on a scale (Mean)
Arm 1 + Arm 38.3
Arm 2 + Arm 48.1
Arm 2 + Arm 38.0
Arm 1 + Arm 48.4

[back to top]

Roland and Morris Disability Questionnaire

"This questionnaire measures disability in everyday function due to back pain. It is a 24-item checklist asking patients to endorse whether or not back pain limits activities they normally do (eg, I stay at home most of the time because of my back). Scores range from 0 to 24, with higher scores indicating greater disability in everyday function due to back pain. The analysis evaluated the 'as randomized' sample at 12 weeks after baseline, after co-varying for baseline (pre-treatment) values." (NCT00964886)
Timeframe: 12 weeks after baseline (or last observation carried forward)

InterventionUnits on a scale. (Mean)
Arm 1 + Arm 38.7
Arm 2 + Arm 48.9
Arm 2 + Arm 38.7
Arm 1 + Arm 48.9

[back to top]